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Summary 
 
 
 
The aetiology of multiple sclerosis (MS) remains largely unknown, due to its multifactorial nature 
with environmental and genetic factors contributing to the risk. Several investigations highlighted 
the important role of the genetic component influencing disease susceptibility and progression. 
 
In the present study genetic variations in the MTHFR (1298 A>C and 677 C>T) and HFE (845 
G>A) genes previously, shown to affect folate and iron metabolism respectively, were studied in 
the context of MS. The aim of the study was to contribute the laboratory component of a pathology 
supported genetic testing approach used to identify a subgroup of MS patients with altered 
nutritional requirements due to genetic susceptibilities. The study population included 90 patients 
with a clinical diagnosis of MS and 49 control individuals, without any signs or symptoms of the 
disease, drawn from the same age- and population group.  
 
Three mutation detection systems were compared in terms of accuracy, sensitivity, cost 
effectiveness and ease of operation in relation to the MTHFR and HFE gene mutations analysed. 
Analytical validity of the genetic assays was an important consideration; therefore the respective 
real-time polymerase chain reaction (RT-PCR) methods were compared with direct DNA 
sequencing as the gold standard. The methodology included use of the ABI™ 7900HT, the Roche 
LightCycler
®
 480 II system and the Corbett Rotor-Gene™ 6000 5-plex HRM. The same genotype 
results were obtained for the DNA samples tested with the three RT-PCR methods. In terms of cost 
effectiveness, ease of operation and optimization, the Corbett Rotor-Gene™ 6000 5-plex HRM 
thermal cycler, with use of the ABI™ TaqMan Genotyping assays was found to be the most 
efficient for mutation detection using relatively small sample batches.  
 
Following successful standardization of the RT-PCR assays, genotype-phenotype correlation 
studies was performed in a subset of 43 MS patients with available data. Biochemical tests were 
previously done on blood samples at the National Health Laboratory Service (NHLS) chemical 
pathology laboratory at Tygerberg Academic Hospital. A novel finding of this study was that 
heterozygotes and homozygotes for mutation 1298 A>C in the MTHFR gene presented with lower 
serum iron levels (12.37 ± 5.91 μmol/l) in comparison to subjects without the C-allele (18.64 ± 7.15 
μmol/l; P = 0.02). Furthermore, C-reactive protein (CRP) levels were found to be marginally 
significantly higher (P = 0.07) in the MTHFR 1298 A>C mutation-positive heterozygotes compared 
  
to subjects without the C-allele (6.65 ± 4.96 mg/l vs 2.93 ± 2.31 mg/l), linking inflammation to the 
presence of the MTHFR 1298 A>C mutation. In comparison, the MTHFR 677 C>T as well as the 
HFE 845 G>A mutation showed no correlation with transferrin saturation, ferritin, haemoglobin or 
CRP levels. The absence of increased iron status in HFE mutation carriers was in accordance 
previous findings suggesting altered iron metabolism in MS patients with this mutation.  
  
For the first time, high-throughput assays for functional polymorphisms in the MTHFR and HFE 
genes can now be offered as a routine service at the Tygerberg Academic Hospital. This application 
is used in combination with blood biochemistry tests as part of a comprehensive gene-based, 
pathology supported screening and intervention program aimed at improved quality of life in 
patients diagnosed with MS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Opsomming 
 
 
 
Die etiologie van meervoudige sklerose (MS) is nog grootendeels onbekend, as gevolg van die 
multifaktoriale aard van die siekte, met omgewings- en genetiese faktore wat bydra tot die risiko. 'n 
Aantal  ondersoeke het reeds die belangrikheid van die genetiese komponent vir die vatbaarheid vir 
die siekte en die progressie daarvan beklemtoon.  
 
In die huidige studie was genetiese variasies in die MTHFR (1298 A>C en 677 C>T) en HFE (845 
G>A) gene bestudeer wat voorheen getoon het dat dit foliensuur- enystermetabolisme 
respektiewelik in die konteks van MS affekteer. Die doel van die studie was om die laboratorium 
komponent van 'n patologie-ondersteunde genetiese toets daar te stel wat gebruik kan word om 'n 
subgroep van MS pasiënte te identifiseer wat veranderderde voedingsbehoeftes het as gevolg van 
genetiese vatbaarheid. Die studiepopulasie het bestaan uit 90 pasiënte met 'n kliniese diagnose van 
MS en 49 kontroles sonder enige tekens of simptome van die siekte, wat ingesluit is vanuit 
dieselfde ouderdoms- en populasiegroep .  
 
Drie mutasie analise sisteme was vergelyk in terme van akkuraatheid, sensitwiteit, 
kostedoeltreffendheid en gemak van gebruik met betrekking tot die MTHFR en HFE geen mutasies. 
Analitiese geldigheid van die genetiese toetse was 'n belangrike oorweging; daarom was die 
onderskeie rieëltyd polimerase kettingreaksie (RT-PKR) metodes vergelyk met direkte DNA 
volgordebepaling as die goue standaard. Die metodologie het die ABI™ 7900HT, die Roche 
LightCycler
®
 480 II sisteem en die  Corbett Rotor-Gene™ 6000 5-plex HRM ingesluit. Dieselfde 
genotipe resultate was met die verskillende metodes verkry vir die DNA monsters wat getoets is 
met die drie RT-PKR metodes. Wat betref kostedoeltreffendheid, gemak van gebruik en 
optimisering, was die gebruik van die Corbett Rotor-Gene™ 6000 5-plex HRM Thermal Cycler, 
met die ABI™ TaqMan Genotyping essays die mees effektief vir mutasie opsporing van relatief 
klein getalle monsters.  
 
Nadat die RT-PKR toetse suksesvol gestandardiseer was, was genotipe-fenotipe korrelasies 
uitgevoer in 'n subgroep van 43 MS pasiënte met die beskikbare data. Biochemiese toetse was 
voorheen gedoen op die betrokke bloedmonsters by die Nationale Gesondheid Laboratorium Diens 
(NHLS) se chemiese patologie laboratorium by Tygerberg Akademiese Hospitaal. 'n Nuwe 
bevinding van hierdie studie was dat heterosigote en homosigote vir die MTHFR 1298 A>C 
  
mutasie gepresenteer het met laer serum yster vlakke (12.37 ± 5.91 μmol/l) in vergelyking met 
individue sonder die C-alleel (18.64 ± 7.15 μmol/l; P = 0.02). Verder was die C-reaktiewe proteien 
(CRP) marginaal betekenisvol hoër (P = 0.07) in die MTHFR 1298 A>C heterosigote in 
vergelyking met individue sonder die C alleel (6.65 ± 4.96 mg/l vs 2.93 ± 2.31 mg/l), wat aandui 
dat inflammasie verhoog mag wees in die teenwoordigheid van die MTHFR 1298 A>C mutasie. In 
vergelyking hiermee het die MTHFR 677 C>T sowel as die HFE 845 G>A mutasies geen korrelasie 
met transferrien versadiging, ferritien, hemoglobien of CRP-vlakke getoon nie. Die afwesigheid van 
verhoogde yster status in MS pasiënte met die HFE mutasie was in ooreenstemming met vorige 
bevindinge wat veranderde ystermetabolisme in MS pasiënte met hierdie mutasie aangedui het.  
  
Vir die eerste keer is hoë deurvoer genetiese toetse nou vir funksionele polimorfismes in die 
MTHFR en HFE gene beskikbaar as 'n roetiene diens by die Tygerberg Akademiese Hospitaal. Dit 
kan gebruik word saam met bloed biochemiese toetse as deel van 'n omvattende geen-gebaseerde, 
patologie ondersteunde intervensie program wat daarop gemik is om die kwaliteit van lewe van 
pasiënte gediagnoseer met MS te verbeter.  
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1.1. MULTIPLE SCLEROSIS 
 
Multiple sclerosis (MS) is a chronic neurological disorder which causes demyelination of axons in 
the brain and Central Nervous System (CNS) resulting from multifocal inflammatory events (Byun 
et al. 2008; Chilcott et al. 2003). MS is more prevalent in women and the onset of disease takes 
place mostly in young adults between 18 and 50 years of age (Weinshenker BG, 1998). Lesions 
formed due to MS are heterogeneous and are differentiated by inflammation, demyelination, and 
variable extent of axonal and oligodendrocyte damage (Bjartmar et al. 2003; Lassmann, 1998; 
Trapp et al. 1999). Several aspects play a role in the development of the disease, including 
environmental factors, such as decreased sunlight exposure, smoking, and the body‟s resistance to 
certain viruses and severe stress. Genetic factors and gene-gene interactions have also been 
proposed to have an effect on the disease process (Debouverie et al. 2008; Helen and David, 1998; 
Review by Marrie 2004; Remington, 1995; Robertson and Compston, 1995). 
 
1.2. NEUROPATHOLOGY OF MS 
 
The myelin sheath is an electrically insulating layer that forms the extended membrane of 
oligodendrocytes, enfolds the axons and allows for impulses to propagate through the neurons at 
high speed. Inflammation resulting from MS ruptures the myelin sheath protecting the axons 
causing demyelination and the formation of lesions (De Stefano et al. 2001; Ferguson et al. 1997; 
Trapp et al. 1999). MS lesions are found in the normal white matter and infrequently in the gray 
matter of the CNS (Lassmann, 1998; Narayana, 2005; Peterson et al. 2007; Trapp et al. 1999). 
Progressive demyelination and oligodendrocyte death results in either decreased nerve conductivity 
or complete loss of nerve impulse transmission, leading to impaired neurological function (Hickey 
et al. 1999; Trapp et al. 1999; reviewed by Reipert, 2004). Axonal injury is mostly irreversible 
(Davie et al. 1999) and the spheroids (swellings) can be detected within the lesions during later 
stages of the disease (McGavern et al. 1999; McGavern et al. 2000).  
 
1.3. SIGNS AND CLINICAL SYMPTOMS OF MS 
 
MS symptoms differ in severity from person to person and episodes are irregular after which the 
patient may go into remission (Byun et al. 2008). This is dependent on the level of axonal damage 
and demyelination in the brain and spinal cord (Kanda, 2003). Symptoms also depend on the 
location of the lesions formed. Clinical signs and symptoms may include chronic disabling fatigue 
that results in co-ordination problems or ataxia (Burnfield, 1996), weakness of the limbs (Beatty, 
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1995; Rasova et al. 2010; Rao et al. 1991), burning sensations and heat intolerance, which may 
exaggerate symptoms (Tandon et al. 1989). In addition, patients may also suffer from 
uncoordinated speech, urinary incontinence and constipation affecting 90% of patients (Langford, 
1994). Spasticity, abnormal eye movements, optic neuritis (blurred and painful vision) and 
depression is found in one third of patients. Cognitive impairment (Bruce and Simon, 1999) is 
thought to be present in 40-70% of patients suffering from MS and is associated with loss of 
memory (Charil et al. 2003; Stapler and Lincoln, 1979). Patients may also suffer from cognitive 
dysfunction relating to sustained attention, conceptional reasoning and verbal fluency (Rao et al. 
1991; Stapler and Lincoln, 1999).  
 
1.4. DISEASE CLASSIFICATION 
 
Classification and detection of MS was first reported by Dr Jean-Martin Charcot in 1868 at 
Salpêtrière Hospital, were he stated the disease as “presence of multiple plaques in the CNS” 
(Murray, 2005: 6).  
 
Several types of MS have been classified as the disease affects each individual with a different 
combination of symptoms and severity.  The four clinically distinct types are: relapsing remitting, 
secondary progressive, progressive relapsing and primary progressive MS (Lublin and Reingold, 
1996).  
 
1.4.1. Relapsing Remitting Multiple Sclerosis  
In Relapsing Remitting MS (RR-MS), patients experience alternating periods of relapse and 
remission of the disease. Each relapse episode may set off new symptoms or exagerate existing 
symptoms. Patients may also undergo remission, which fluctuates greatly in time period and level 
of severity (Millefiorini et al. 1997). During this phase, which may proceed days to months, the 
symptoms often decrease or become absent (Lublin and Reingold, 1996; Pittock and Rodriquez, 
2008). RR-MS accounts for 85-90% of MS cases (Mendes et al. 2003).  
 
1.4.2. Secondary Progressive Multiple Sclerosis 
This is the second phase of relapsing remitting MS seen in 90% of patients (Annapurna et al. 2002). 
The disease exacerbates as remissions take place and the number of relapses decreases. 
Approximately 40% of RR-MS patients enter this phase after 10 years and 60% within 25 years 
after disease onset (Lublin and Reingold, 1996; Rovaris et al. 2006).   
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1.4.3. Progressive Relapsing Multiple Sclerosis 
Progressive Relapsing MS involves a steady neurologic decline with minimum recovery from acute 
attacks (Trojano and Paolicelli, 2001). This subtype is rare and found only in 5% of individuals 
suffering from MS (Lublin and Reingold, 1996).  
 
1.4.4. Primary Progressive Multiple Sclerosis 
Primary Progressive MS (PP-MS) is characterized by gradual disability in patients with no 
remissions (Lublin and Reingold, 1996; Trojano and Paolicelli, 2001). This type arises in 10-15% 
of MS patients. The onset of PP-MS typically commences in the late thirties or early forties and is 
often the most severe form of the disease (Cottrell et al. 1999; McDonnell and Hawkins, 2002; 
Miller and Leary, 2007).  
 
1.5. POSSIBLE CAUSES OF MS 
 
MS is a complex disease driven by several factors rather than a single cause. Genetics and the role 
of environmental factors are the primary focus of present studies. Understanding the genetic roots 
of MS could uncover the basic mechanism of disease, thereby leading to discoveries of treatments 
and possible prophylactic measures. Other theories concerning the cause of MS include viral 
infection and autoimmunity.  
 
1.5.1. MS and Autoimmunity 
For many years it has been proposed that MS is an autoimmune disease (Baranzini and Hauser, 
2002; Peterson et al. 2007). Autoimmunity results from the immune system failing to recognize the 
constituents of an individual‟s body as “self”, proceeding into an immune response against cells and 
tissues (Chilcott et al. 2003; Stefanova et al. 2002; Jerne, 1974). Several mechanisms have been 
proposed which may play a role in autoimmune diseases. These include Molecular Mimicry, where 
a viral antigen shares structural similarities with the native proteins (Hafler, 2004). This results in 
antibodies binding to both the pathogenic antigen as well as a self-antigen, amplifying the immune 
responses, which consequently gives rise to autoimmunity. The other is cytokines which are the 
main factors involved in immune regulation and initiation of autoimmunity.  Specialized 
immunoregulatory cells such as regulatory T cells exert their effect either through suppressing or 
enhancing the immune response. This depends on their production via cytokines, which may 
ultimately result in autoimmunity (Vanderlugt and Miller, 2002; Von Herrath et al. 2003). 
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The CNS is often thought to be an immuno-privileged site. However, T cells have been detected 
within the CNS as inspectors for any injury or infection. The entry of T cells into the CNS is made 
possible through penetration of the blood brain barrier (BBB) (Hickey et al. 1991; Wekerle et al. 
1987). T and B cells have auto-reactive characteristics and in some cases, healthy individuals have 
also been shown to stimulate T cell activation via myelin elements with no signs of pathogenesis.   
 
The autoimmunity theory states that the activation of T cells only occurs when tolerance is lost, i.e. 
ability of an individual‟s immune system in differentiating „self‟ from „non-self‟ (Diaz-Villoslada et 
al. 1999; Sprent and Kishimoto, 2001). On activation of myelin-specific T cells, penetration of 
immune cells into the CNS across the blood-brain barrier (BBB) is allowed. Once in the CNS, 
secretion of pro-inflammatory cytokines and B Cells takes place (Hogquish et al. 2005). Myelin-
specific CD4+ T cells are considered to be the initiators of disease in MS patients (Babbé et al. 
2000; Jacobsen et al. 2002). This is done through their interaction with the antigens presented on 
the myelin sheets, resulting in inflammation and damage to myelin, oligodendrocytes and the axons 
(Zamvil and Steinman, 2003). However, this theory is currently considered controvertial 
(Chaudhuri and Behan, 2005), since this model originated from an animal model, experimental 
allergic encephalomyelitis (EAE) presenting brain inflammation, which is not similar to MS in all 
respects (Sriram and Steiner, 2005).  
 
1.5.2. Infections and Viral Factors Concerning MS 
There have been many theories and hypotheses concerning the actual initiation of MS in people 
apart from genetic factors, for example pathogenic infections.  
The hygiene hypothesis states that autoimmune diseases result from a lack of exposure to multiple 
infective microorganisms in childhood due to excessive hygiene and advanced medication 
(Ascherio and Munger, 2007; Fleming and Fabry, 2007), whereas the prevalence hypothesis 
proposes that MS is caused by a single pathogen found in regions where MS prevalence is much 
higher. Once the pathogen reaches the desired site it causes persistent infection but 
asymptomatically. Therefore, no signs or symptoms are detected for many years until infection has 
spread far enough to cause demyelination (Ascherio et al. 2007; Kurtzke, 1993). A number of 
viruses have been linked to MS including Human herpes viruses, Varicella zoster virus and 
endogenous retroviruses such as the human endogenous retrovirus (HERV) (Christensen, 2007; 
Perron and Lang, 2010, Sotelo et al. 2008).  
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1.5.3. Oligodendrocyte Apoptosis 
An alternative theory for the aetiology of MS is the apoptotic cell death of oligodendrocytes, the 
cells that produce myelin. In this paradigm, the immune system is not the primary cause of the 
disease, but functions to remove dead or damaged tissue. This is illustrated by the work of Barnett 
and Prineas (2004). When they examined newly-forming lesions, they found no peripheral immune 
cells. Instead, they observed fields of apoptotic oligodendrocytes. These cells were then 
phagocytised by microglia, which also stripped away myelin from the axons. Subsequently, 
peripheral immune cells penetrated the BBB. The most recent work from the laboratory of Prineas 
indicates that asctrocytes, the cells surrounding blood vessels and which are responsible for nutrient 
uptake into the brain, are also damaged in MS (Parratt and Prineas, 2010).  
 
 
1.6. DIAGNOSIS  
 
Early diagnosis of MS is important to minimize disease progression and demyelination of axons. 
The disease is often diagnosed in RR-MS patients between 15 and 60 years of age as they reveal 
symptoms indicative of CNS lesions, as opposed to other types of MS, which are often devoid of 
early symptoms (Thompson and Donald, 1996). Upon clinical examination, the involvement of two 
or more areas of CNS and related abnormalities should be found. Diagnosis is made possible 
through the use of Magnetic Resonance Imaging (MRI, Figure 1.1) and other electrophysiological 
tests such as Visual Evoked Potentials (VEP) used in clinical practice (Halliday et al. 1973; 
Offenbacher et al. 1993) which reveal abnormalities in anterior optic pathways (Annapurna et al. 
2002) and Brainstem Auditory Evoked Potentials (BAEP) (Lublin and Reingold, 1996; Weinstock-
Guttman et al. 1995).  
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Figure 1.1. Image obtained through application of MRI of a relapsing remitting 
MS patient. Red arrows indicate lesions in the white matter of the brain caused by 
demyelination. (Source: Prof SJ van Rensburg, with permission) 
 
 
In approximately 90% of patients, increased oligoclonal immunoglobin G (IgG) bands are found in 
the CSF.  IgG is evoked through inflammation, however, oligoclonal bands are not a diagnostic tool 
for MS.  
 
 
1.7. THERAPY MANAGEMENT  
 
The management of MS is a complex and intricate issue, due to the vast diversity of symptoms in 
affected patients and the lack of a well-defined cause of the disorder. This has lead to the 
involvement of a wide variety of different clinical specialists in the therapeutic process, from 
neurologists and physiotherapists to occupational and speech therapists. The elusive nature of the 
pathogenic process underlying MS has resulted in a number of therapies strictly designed to 
improve the quality of life of the affected patients, as no universal cure for all forms of the disorder 
has yet been discovered. The treatments are focused on reducing the number of relapses, preventing 
or reducing the resulting neural damage and delaying the onset or progression of the disease.  
 
Therapies used in MS have been categorized according to severity and disease type being treated. 
Current practice involves disease-modifying therapies aimed at suppression of the immune system.  
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1.7.1. Acute Corticosteroid Treatment 
During the acute exacerbation stage of MS, intravenous methylprednisolone is given for 3 to 5 days 
(Tremlett et al. 1998), which has been proven to speed up the recovery (Beutler et al. 1996). This is 
due to the anti-inflammatory effect, as well as immunosuppressive characteristics of corticosteroids 
(Beutler et al. 1996; Romine et al. 1999; Sipe et al. 1994; Tremlett et al. 1998).  
 
1.7.2. Interferons 
One of the therapies modifying the disease status focuses on Beta Interferon (IFN) (Bidot et al. 
2007; Chilcott et al. 2003). Interferons are cytokines that are triggered upon viral infection and thus 
prevent cell infection. The autoimmune response of interferons can be seen via the action of 
Gamma interferons secreted by T cells, which act upon macrophages, aggravating the disease state 
and destroying the myelin sheath. IFN influences this process by inhibiting leukocyte proliferation 
and antigen presentation. It also restrains T-cells from migrating across the BBB and alters 
cytokines for production of an anti-inflammatory environment (Yong et al. 1998). This effect of 
IFN, mainly IFN-1a and IFN-1b, is referred to as immunomodulatory action (Tandon et al. 
1989; Weinstock-Guttman et al. 1995). Some of the drugs in use include Avonex (IFN-1a), given 
via injection at doses of 30 g (6 million IU) once a week, Rebif (IFN-1a) is used three times a 
week at a dose of 22 g (6 million IU) and Betaferon (IFN-1) injected on alternative days at a 
dosage of 0.25 mg (8 million IU) (Annapurna et al. 2002). One of the main side effects known 
when using any of these treatments is flu-like symptoms, which can be reduced via a non-steroidal 
anti-inflammatory drug (NSAID) prior to interferon usage.  
 
1.7.3. Glatiramer acetate (Copolymer-1) 
One of the myelin analogues is glatiramer acetate, which is a synthetic polypeptide (Bidot et al. 
2007; Chilcott et al. 2003). Although Glatiramer acetate‟s mode of action is not yet known, studies 
suggest that it suppresses T cell activation and inhibits lymphocyte migration (Miller et al. 1998; 
Prat et al. 1999). This is achieved when Glatiramer acetate competes with myelin basic protein and 
other myelin auto-antigens for binding sites on Major Histocompatibility Complex (MHC) Class II 
found on antigen presenting cells (Arnon et al. 1995). In a double-blind placebo trial conducted by 
Johnson et al, it was found that a dosage of 20 mg of glatiramer acetate in RR-MS patients 
decreased the relapse rate by up to 29% (Johnson et al. 1995; Johnson et al. 1998).    
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1.7.4. Intravenous Immunoglobin G (IgG) 
Apart form the use of IgG as a marker in diagnosing MS, it is now known that this immunoglobin 
(Ig) molecule can play a role in disease treatment (Fazekas et al. 1997). Its mode of action imitates 
that of the binding of the Fc (Fragment crystallizable) Receptor portion of Ig molecules to the B 
cells, thus generating negative signals which ultimately cause B cell down-regulation (Bidot et al. 
2007; Yan et al. 1990). Treatment involves intravenous delivery of 0.15 - 2g/kg of immunoglobin 
per month (Fazekas et al. 1997). This has a direct effect on relapse-rate though side effects have 
been identified in some cases which may include malaise, fever, headache, rash, and thrombo-
embolism (Sorensen et al. 1998).  
 
1.7.5. Methotrexate  
Methotrexate has been shown to suppress the progression of chronic progressive MS when used in 
low doses. This requires the use of 7.5mg of the drug once every week (Goodkin et al. 1995). The 
use of this drug would however be contra-indicated in patients who have mutations in 1-carbon 
metabolism (Van Rensburg et al. 2010). 
 
1.7.6. New MS Drugs 
Several new drugs, including 2 emerging oral agents for MS, have been submitted to the US Food 
and Drug Administration (FDA) for approval. The advantage of the newer generation drugs is that 
they are more effective than IFN and they do not have to be injected. However, they are much 
more expensive and they may have serious side effects in some patients. 
 
1.7.6.1. Natalizumab (Tysabri), marketed by Biogen Idec/Élan, is a humanised monoclonal 
antibody against the cellular adhesion molecule α4-integrin. After its approval by the FDA in 2004, 
it was subsequently withdrawn after it was shown to cause progressive multifocal 
leukoencephalopathy (PML) in some of the patients. It was however reapproved in 2006 under a 
special prescription program. However, by January 2010, 31 cases of PML cases had been reported. 
It is currently not recommended as first-line treatment in MS (Foley, 2010). 
 
1.7.6.2. Leustatin (Cladribine; 2-chlorodeoxyadenosine triphosphate, trade name Leustatin) was 
originally developed as an anti-cancer drug, but was subsequently investigated as an oral agent for 
MS since it selectively targets CD4+ and CD8+ cells (Giovannoni et al. 2010). However, CD4+ cell 
counts remained low after treatment. The benefits were that cladribine significantly decreased the 
annualized relapse rate by almost 60% and decreased mean brain lesion count by 88% from 
baseline. However, the adverse events included 4 cases of carcinoma (Giovannoni et al. 2010). 
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Cladribine was approved for marketing in Australia and Russia, but on September 24, 2010 the 
Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency 
(EMA), refused an application by Merck to market Cladribine in Europe, since they ruled that the 
benefits of Cladribine did not outweigh its risks. It is not known whether the FDA will approve the 
drug. (Source: downloaded 25/09/2010 http://www.medscape.com/viewarticle/729387). 
 
1.7.6.3. Fingolimod 
On September 22, 2010 the FDA announced Fingolimod (Gilenya, Novartis), to be the first 
approved oral treatment for MS. Fingolimod acts as a superagonist to sphingosine-1-phosphate 
receptors on lymphocytes, reducing their overall number in circulation. Over 2 years, Fingolimod 
showed decreased relapses (annualised relapse rate of 0.18 compared to 0.40 with placebo) and 
delayed disability progression (regression of 17.7% compared to 24.1% with placebo) in patients 
with relapsing forms of MS. However, some patients discontinued the study due to 
bradycardia/atrioventricular conduction block, elevated liver-enzyme levels, macular edema or 
hypertension (Kappos et al. 2010). 
 
1.8. Genetic and Environmental Aspects of MS 
 
MS is considered to be a multi-factorial disease with both genetic and environmental components. 
MS affects 1 million individuals worldwide, that is approximately one in every thousand (0.1%) 
individuals in a given population, but the prevalence varies between different countries (Anderson 
et al. 1992; Courtney et al. 2009). 
 
1.8.1. Genetic Factors 
The potential role of genetics implicated in MS pathology has been increasingly recognized and 
research studies have thus focused on finding the series of genes involved as well as the inheritance 
pattern of the disease. It has also been indicated that one in every five people with MS has a familial 
history of the disease and the risk of inheriting MS in closely related relatives (including first, 
second and third degree relatives) is about 5% (Compston and Coles, 2002). In addition, twin 
studies provide an estimation of the contribution of the role of genetic and environmental factors 
through comparison of concordance rates in monozygotic twins (identical) and dizygotic twins 
(fraternal). The genetic effect is proven to have a higher concordance rate in monozygotic twins, 
where the risk of one twin increases to 300 per 1000 (30%) when the other twin is affected by the 
disease (Bobowick et al. 1978; Ebers and Sadovnick, 1994; Kalman and Lublin, 1999; Mackay and 
Myrianthopoulos, 1966; Weinshenker et al. 1989).  
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Extensive studies have been done to discover the genes responsible or contributing to the 
development and progression of MS. Recent genetic findings have indicated that MS is caused by 
defects in a series of genes that directly or indirectly play a role within pathways associated with 
MS development (Hoffjan and Akkad, 2010). Several vitamin D-related proteins have been 
identified that may influence the pathology of MS, with conflicting results (Fukazawa et al. 1999; 
Niino et al. 2000; Niino et al. 2002; Partridge et al. 2004; Smolders et al. 2009; Steckley et al. 
2000; Tajouri et al. 2005; Yeo et al. 2004). Most recent findings have indicated a link between 
Vitamin D and gene polymorphisms in HLA alleles in MS (Niino et al. 2000; Ramagopalan et al. 
2009). These include HLA-DR2 haplotype DRB1*1501, DQB1*0602, HLA-C5 and HLA-
DRB1*11 susceptibility loci (Dean et al. 2008; Ramagopalan et al. 2007; Review by Compston and 
Coles, 2008). The HLA-DRB1*1501 haplotype contributes the highest genetic risk of MS 
development in those of Northern European ancestry (Ramagopalan et al. 2009; Review by 
Ascherio et al. 2010).  
 
1.8.2. Environmental Factors 
The role of environmental factors in the development of MS has gained greater support since 
epidemiological data revealed an unequal geographical distribution of the disease (Courtney et al. 
2009). Increasing evidence support the notion that, similar to other multi-factorial diseases, 
different combinations of environmental and lifestyle risk factors could trigger the disease in 
genetically susceptible individuals. 
 
The prevalence rate of MS ranges from 2 to 150 per 100,000 individuals (0,002% to 0,15%) 
(Granieri et al. 1993). In the study done by Kurtzke in 1985, geographical patterns of MS were 
identified in relation to latitude suggesting that the regions further away from the equator (both 
north and south of the equator), were at higher risk of developing the disease. Residents in the 
northern hemisphere were predominantly found to have a higher risk of developing MS than those 
in the southern hemisphere. The risk is greater in females than in males with the ratios between 1.5 
and 2.5 in most populations. In high-risk populations the risk for MS in women is 1 in 200 
(Henriksen and Hyllesred, 1988; Henriksen, 1999; Herna et al. 1999; Mayer et al. 2003; Orton et al. 
2006). MS prevalence decreases to 5 cases per 100 000 people in Asia as well as in tropical and 
subtropical regions (Ascherio et al. 2007; Compston et al. 2006; Kurtzke, 1995; Rosati, 2001). 
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Figure 1.2. World Wide Prevalence of MS per 100 000 population (Adapted from 
Review by Marrie 2004).  
 
Moreover, the risk of developing the disease after immigration to lower risk areas – such as South 
Africa, Hawaii or Dutch Antilles – past the age of 15 remains unchanged, while immigration under 
the age of puberty acquired the frequency of the indigenous population of the country of destination 
(Alter et al. 1971; Dean, 1967; Gale and Martin, 1995; Hammond et al. 2000; Kurtzke, 1985; 
Moffie, 1966). This may be due to the link between childhood infections and MS as the age of 
migration is a modifying factor in the disease process (Alter et al. 1962; Alter et al. 1966). 
 
Environmental factors contribute greatly to MS. Infection is one of the factors that has received 
significant attention from MS researchers in South Africa (de Villiers et al. 2006) and elsewhere 
(Reviewed by Ebers 2008). It has been proposed that viral infection is one of the contributing 
factors in the aetiology of MS (Cosby et al. 1989; Haase et al. 1981; Hammerschlag et al. 2000; 
Stevens et al. 1980), but no conclusion has been reached regarding the time of infection, the 
severity or presence of clinical symptoms (Reviewed by Marrie 2004; Weiner, 1998).  
 
A great deal of research has been focused on unravelling the apparent link between viral infection 
and MS, resulting in the discovery of an increased prevalence of antibodies to several viruses in the 
serum and CSF of patients suffering from MS when compared to that of the control population 
(Cook and Dowling, 1980; Haire, 1977).  However, these finding were less evident when compared 
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to siblings, patients with the same HLA type or patients with neurological or non-neurological 
inflammation (Shirodaria et al. 1987; Visscher et al. 1981). Epstein-Barr virus (EBV) is one of the 
factors that is thought to have a primary role in the pathogenesis of MS (Compston et al. 1986; 
Shirodaria et al. 1987; Bray et al. 1983). Infection with EBV is mild in children, while in adults it 
causes infectious mononucleosis. Acute infection may lead to latent infection of B-lymphocytes 
(Straus, 1993). Several case and cohort studies have indicated an increased level in the EBV 
antibody serum titres in the MS population (Ascherio and Munch, 2007; Haahr et al. 1995; Hernan 
et al. 2001), whereas some did not (Casetta et al. 1994; Gusev et al. 1996; Lenman and Peters, 
1969; Poskanzer et al. 1980; Souberbielle et al. 1990; Italian Multiple Sclerosis study group, 1989). 
Thus current evidence is insufficient to prove that EBV causes MS.  
 
Vitamin D is one of the environmental factors that have been strongly associated with development 
of MS (Ascherio and Munger 2007; Burton et al. 2008; Cantorna et al. 1996; Smolders et al. 2008; 
Soilu et al. 2005; van der Mei et al. 2007). Extensive studies have been done throughout the world 
in order to link Vitamin D exposure and latitude in correlation to MS (Acheson et al. 1960; 
Kurtzke, 1967; var der Mei et al. 2001). It has been indicated that the rate of mortality from MS is 
less in the residence in high sunlight exposure regions (Freedman et al. 2000). In a study done in 
Australia, high sunlight exposure during childhood has been shown to have lower risk in MS 
development (van der Mei et al. 2003). Also, higher outdoor activity during childhood in Northern 
Norway has been illustrated to reduce the risk of MS (Kampman et al. 2007). In addition, a study 
done amongst American nurses reported that high dosage intake of dietary vitamin D ( 400 
IU/day) resulted in higher serum 25(OH)D i.e. the major circulating form of vitamin D in the blood 
via Vitamin D binding protein (Myhr, 2009), which led to a 40% reduction in risk of developing 
MS (Munger et al. 2006). This correlates to studies that have demonstrated low serum vitamin D 
levels in 50 to 70% of MS patients (Nieves et al. 1994; Mahon et al. 2003; Soilu et al. 2008; 
Ozgocmen et al. 2005). Additionally, this corresponds to evidence that has indicated lower vitamin 
D levels in patients suffering from RR-MS during relapses (Soilu et al. 2005; Soilu et al. 2008; 
Smolders et al. 2008). Also, the rate of relapse occurrence has been associated with the level of 
vitamin D and sunlight exposure (Tremlett et al. 2008).  
 
The effect of smoking as an environmental risk factor for early conversion of MS to clinically 
defined disease and risk for progression in MS has been studied extensively. In a follow-up study of 
36 months performed in 129 patients with a clinically isolated syndrome, disseminated white-matter 
lesions on brain MRI resonance imaging, and positive oligoclonal bands in the cerebrospinal fluid, 
it was found that smoking is an independent but modifiable risk factor for disease progression. The 
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recommendation from this study was that this aspect should be considered in the counselling of 
patients with a clinically isolated syndrome (Pauli et al. 2008). The negative effect from smoking is 
most obvious in smokers who started early as it clearly worsens the prognosis of MS even in past 
smokers (Sundstrom and Nystrom 2008).  
 
 
1.9.   FOLATE AND MYELINATION 
 
Due to the neurodegenerative characteristics of MS, pathways involved in myelin production have 
been researched for many years. One of the pathways involved in myelin production is the folate - 
vitamin B12 - methyl transfer pathway. Continuous availability of nutrients that are for example 
required as co-factors of enzymes involved in myelin production or maintenance needs to be 
emphasised (Selzer et al. 2003).  Methylation is of particular importance for myelin production and 
maintenance, as may be reflected by the increased risk of MS associated with adolescent obesity 
(Munger et al. 2009). While this finding highlights the importance of a healthy diet for weight 
management in general, it also provided valuable insight on how susceptibility factors for the 
development or the severity of chronic diseases may be further compromised by the additional 
burden of obesity as a reflection of an inappropriate diet. Both obesity and smoking, implicated as 
important environmental / lifestyle risk factors for MS, are associated with raised homocysteiene 
levels. This could reflect nutrient deficiencies (e.g. folate, vitamin B12, zinc) that are essential for 
optimal myelin production and maintenance. 
 
In absence or deficiency of nutrients required as co-factors for optimal activity of enzymes involved 
in the folate-Vitamin B12 pathway, a genetic defect(s) can be triggered and lead to disease 
development. Additionally, inhibition of these pathways through mutation, nitrous oxide and 
increase in the level of homocysteine may contribute to demyelination and neurodegeneration (van 
Rensburg et al. 2006).  
 
1.9.1. Methylenetetrahydrofolate reductase  
Methylenetetrahydrofolate reductase (MTHFR) is an enzyme involved in regulation of folate and 
homocysteine (Hcy) metabolism. The enzyme reduces the 5,10-methylenetetrahydrofolate (5,10-
MTHF) to 5-methyltetrahydrofolate (5-MTHF), (Klotz et al. 2010; Goyette et al. 1994). Folate is a 
cofactor in the remethylation of homocysteine and thus absence or deficiency of it results in high 
homocysteine levels in the plasma. During homocysteine metabolism, the neurotoxic intermediate 
homocysteine, is remethylated into methionine through the catalytic action of activated methionine 
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synthase by methylcobalamin (Vitamin B12 coenzyme) (Kocer et al. 2009). Methionine, also found 
in dietary protein, then acts as a precursor of S-adenosylmethionine (SAM), which has an anti-
inflammatory function and is crucial in the synthesis of phospholipids and myelin generation in the 
CNS (Rosenblatt, 1995; Surtees et al. 1991). Additionally 5,10-MTHF is necessary for nucleic acid 
synthesis by conversion of deoxyuracilmonophosphate (dUMP) to deoxythyminemonophosphate 
(dTMP) for de novo thymidine synthesis (Klotz et al. 2010).  
 
Thus the importance of MTHFR activity in these pathways makes it an attractive candidate for 
analysis of functional genetic variants in diseases involving myelin pathology. It has been reported 
that MS patients have elevated concentrations of homocysteine in their plasma and CSF (Goyette et 
al. 1994; Besler and Comoglu, 2003; Ramsaransing et al. 2006; Reynolds et al. 1992). This may be 
due to deficiency in vitamin B12, folate or destruction in the enzymatic activity responsible for the 
metabolism of homocysteine (Vrethem et al. 2003). The gene that codes for the MTHFR enzyme, 
MTHFR, is located on chromosome one at position p36.3 (Goyette et al. 1994) and contains 11 
exons (Frosst et al. 1995).  
 
Reduced enzyme activity resulting in hyperhomocysteinemia has been linked to variation in the 
MTHFR gene. Two functional polymorphisms at nucleotide positions 677 (C>T, rs1801133) and 
1298 (A>C, rs1801131) are the most ectensively studies variations in the MTHFR gene.  
 
The point mutation 1298 A>C in the MTHFR gene (rs1801131) results in the substitution of alanine 
for glutamine at amino acid position 429 (Glu-429-Ala or E429A) of the regulatory domain of the 
enzyme (Rozen, 1997, van der Put et al. 1998). It causes increased concentrations of 5,10-MTHF 
during nucleic acid synthesis and cell proliferation in the course of inflammation (Linnebank et al. 
2004). This reduces the levels of SAM, which diminishes the regeneration of phospholipids and 
myelination, a pathophysiological effect implicated in MS (Surtees et al. 1991). In the German 
case-control study conducted by Klotz et al. in (2009), MTHFR 1298 A>C was found to influence 
neurodegeneration and the incidence rate of MS. This association has received further support from 
an American study, which concluded that defects in the folate sensitivity of the homocysteine 
metabolism may affect disease status (Susser et al. 1998).  
 
The MTHFR mutation designated 677 C>T (rs1801133) results from a cytosine to thymine change 
at position 677, which causes a substitution of valine for alanine at amino acid position 222 (Ala-
222-Val or A222V) of the enzyme (Frosst et al. 1995). This mutation has been linked to a reduction 
in activity and increase in thermolability of the MTHFR enzyme (Jacques et al. 1996; Schwahn and 
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Rozen 2001; Yamada et al. 2001).  The mean activity in the Ala-Val heterozygote is 65% with 30% 
reduced activity in the Val/Val homozygous state (Tajouri et al. 2006). The frequency of the 
polymorphism varies significantly between ethnic groups (Schneider et al. 1998). The MTHFR 
677TT genotype occurs in approximately 10% of individuals in the North American population, 
which is similar to the frequency reported in the South African Caucasian population (Scholtz et al. 
2002). The 677TT individuals are predisposed to mild hyperhomocysteinemia due to a decrease in 
the MTHFR enzymatic activity (Frosst et al. 1995).  
 
The effect of the 677TT genotype on neurodegeneration was examined in a Japanese study 
consisting of 1 721 subjects with no history of stroke but diagnosed with white matter lesions via 
MRI assessment. The study reported an association of the MTHFR 677TT genotype with silent 
brain infarcts and advanced white matter lesions (Kohara et al. 2003). The study by Klotz et al. 
(2010) on the effect of the 677C>T mutation demonstrated elevated enzymatic activity in cultured 
fibroblasts and peripheral lymphocytes (Klotz et al. 2010). Some studies have found elevated levels 
of homocysteine in the CSF of MS patients (Baige et al. 1995; Besler et al. 2003; Klotz et al. 2010; 
Kolesar, 2000; Tajouri et al. 2006; Vrethem et al. 2003). This suggests that it may be possible to 
regulate the disease state, including the course and extent of myelin damage, by manipulation of the 
essential nutrients relevant to the myelination process (van Rensburg et al. 2006).  
 
 
1.10.   IRON AND MYELINATION  
 
1.10.1 Myelination 
Oligodendrocytes need iron to produce myelin (Connor and Menzies, 1996). Iron is essential for the 
functioning of several prosthetic groups in the cells. This includes heme and iron-sulfur clusters 
(Galy et al. 2005). The brain has been identified as one of the most iron-rich organs (Hallgren and 
Sourander, 1958). Oxidative metabolism requires iron as its basic component and the brain has been 
found to carry out oxidative metabolism at a very high rate, thus resulting in high levels of iron 
usage (Ikeda and Long, 1990).   
 
Oligodendrocytes, illustrated in figure 1.2, are one of the types of cells found in the brain that are 
rich in iron (Connor et al. 1993; Levine, 1991). Oligodendrocytes are located within the white 
matter regions of the brain, near neural cell bodies and along blood vessels (Connor, 1992; Curnes 
et al. 1988; Rajan et al. 1976). Their primary function is the production and regeneration of myelin, 
which requires iron both directly and indirectly (Connor and Menzies, 1996) 
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Figure 1.3. A diagram of the oligodendrocytes responsible for myelination (Adapted 
from McGraw Hill online learning centre).  
 
Oligodendrocytes require iron to act as cofactors for cholesterol and lipid biosynthesis, which are 
key components of the myelin sheath (Larkin and Rao, 1990). Iron-requiring enzymes and 
coenzymes, which catalyze the two pathways both for synthesis and degradation of lipids and 
cholesterol, are enriched in oligodendrocytes (Bourre et al. 1984; Cammer, 1984; Tansey and 
Cammer, 1988). Moreover, oligodendrocytes carry out cholesterol and lipid biosynthesis at a higher 
rate than any other cell types found in the brain (Cammer, 1984; Pleasure et al. 1984).  
 
Iron is indirectly involved in myelin production via its role in oxidative metabolism (Cammer, 
1984; Hyden and Pigon, 1960). Enzymes such as glucose-6-phosphate dehydrogenase, succinic 
dehydrogenase, Nicotinamide Adenine Dinucleotide (NADH) and cytochrome oxidase require iron 
for their catalytic action in oxidative metabolism (Cammer, 1984). This highlights the importance 
of iron in the myelination process, as its deficiency affects activities carried out in the 
oligodendrocytes and thus myelin production. Neurodegenerative diseases that cause 
demyelination, in particular MS, may thus be affected by the deficiency and/or deregulation of iron 
(Adams 1988; Craelius et al. 1982; Drayer et al. 1987; Jensen et al. 2007; Kotze et al. 2001; 
LeVine and Chakrabarty 2004; LeVine et al. 1999; Zamboni, 2006). This is in contrast to disorders 
such as hereditary haemochromatosis (HH), in which the pathogenesis and associated tissue damage 
result from iron overload (Sheldon, 1935; Von Recklinghausen, 1889).  
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1.10.2. Iron Regulation  
Cells absorb iron and heme from the diet via Fe
2+
 transporters such as the divalent metal transporter 
1 (DMT1), divalent cation transporter 1 (Mims et al. 2005), macrophage protein 2 or heme carrier 
protein 1 (Shayeghi et al. 2005). Iron is then transported to plasma from the enterocytes through 
ferroportin (Donovan et al. 2005), which results in oxidation of ferrous to ferric iron by the multi-
copper oxidase protein, haephestin. Serum transferrin (Tf) binds one or two Fe
3+
 atoms. Iron bound 
to Tf is then circulated in the serum and extra-vascular spaces, acting as iron transport protein for 
cells and tissues such as liver, heart and bone marrow (Aisen et al. 1998). The excess intracellular 
iron is stored in ferritin, which has a structure that is composed of 24 H and L subunits allowing for 
iron storage (Harrison and Arosio, 1996). When cells in the body require more iron it is released 
from ferritin (Kidane et al. 2006).  
 
The ability of iron to take part in many reduction-oxidation (redox) reactions such as oxidative 
metabolism, oxygen delivery and storage,  DNA replication and repair, lipid metabolism and many 
more, makes it one of the essential cofactors utilized in the body. Hence its deficiency may be 
involved in a wide range of diseases. Given its importance in health and disease, iron regulation and 
its mechanism of action has been studied extensively (Dunn et al. 2007; Escolar et al. 1999; Hentze 
et al. 2004; Kaplan et al. 2006; Philpott and Protchenko, 2008; Rouault, 2006).  
 
Cellular iron concentration is regulated via the iron regulatory proteins, IRP1 and IRP2, which are 
ubiquitous regulators of cellular iron homeostasis (Galy et al. 2005; Puig et al. 2008). IRP1 and 
IRP2 are cytosolic RNA-binding proteins that post-transcriptionally modulate the translation of 
proteins involved in iron storage (ferritin), transport (transferrin receptor 1) and use via many 
enzymes (Dycke et al. 2007).  
 
In a study done by Rouault, loss-of-function mutations (-/-) of IRP1 and IRP2 mice were generated 
through homologous recombination in embryonic cell lines, in order to illustrate the underlying 
mechanisms of iron regulation (Rouault et al. 2006). Loss of IRP1 function showed no 
abnormalities or dysregulation in iron metabolism, whereas IRP2 -/- mice developed a progressive 
neurologic syndrome associated with abnormalities and myelin degeneration such as microcytic 
anaemia, erythropoietic protoporphyria and neurodegeneration (Cooperman et al. 2005; LaVaute et 
al. 2001). Furthermore, ferritin over-expression was detected in affected neurons and in 
oligodendrocytes due to axonal damage. The experiment with IRP1 -/- and IRP2 -/- mice revealed 
that IRP2 exerts a dominant regulatory function in iron metabolism in vivo (Rouault, 2006).  
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The role of iron-related genes has also been investigated in South African patients with MS (Kotze 
et al. 2001, 2006). In 1999, Rooney et al. described MS, porphyria-like symptoms and a history of 
iron deficiency anaemia in a family of Scottish descent. In addition, van Rensburg et al. (2006) 
found low serum iron concentrations in approximately 50% of patients with MS.  The hypothesis 
that mutations in the IRP2 gene may be associated with iron dysregulation in MS patients has been 
investigated in an previous study (Jalali 2008, BSc Hons thesis). 
 
1.10.3. HFE 
The HFE gene is located at chromosome position 6p21.3 with a length of 9.5 kilobases (kb) 
(OMIM +235200). The structure of HFE resembles that of the major histocompatibility complex 
(MHC) class 1 gene group. The protein encoded by this gene is a type 1 transmembrane 
glycoprotein (Lebron et al. 1998). The HFE gene has been associated with haemochromatosis 
(HH), an iron overload disorder (Feder et al. 1996) presenting a multigenic nature (Review by 
Piertangelo, 2006).  
 
The HFE protein consists of three extracellular domains (α1-3), an untranslated cytoplasmic-3‟ tail 
and a final transmembrane domain with each component encoded by an individual exon (Bahram et 
al. 1999; Feder et al. 1996; Parkkila et al. 1997; Riegert et al. 1998). The α1 and α2 globular 
domains form an eight-stranded anti-parallel β-sheet platform, which is topped by two α helices and 
maintained on the surface of an immunoglobulin constant-like α3 domain. Another key feature is 
the cysteine residues within the α2 and α3 domains, responsible for disulfide bridge formation, 
which are analogous to those of MHC class 1 proteins. This similarity suggests involvement in the 
secondary and tertiary structure of the predicted 343 amino acid glycoprotein that HFE codes for 
(Bjorkman and Parham 1990; Feder et al. 1996; Feder et al. 1997; Lebrοn et al. 1998; Riegert et al. 
1998). The cell surface expression of the protein is facilitated through the interaction between its α3 
domain and β2 microglobulin, forming a heterodimer (Bahram et al. 1999; Feder et al. 1997). In the 
case of MHC proteins, the α1 and α2 helices create a groove for peptide binding, contrary to HFE, 
which does not bind proteins. Crystallographic studies have proven that the HFE α1 helix is located 
close to the α2 helix, forming a shallower and narrower groove than the MHC peptide-binding 
groove. The differences between these proteins regarding their physical structure imply that each 
one has a unique role in the intracellular transferrin-mediated iron uptake (Feder et al. 1998). A 
cluster of four histidine residues, resembling the structure of iron-binding sites found in many 
proteins, has been identified on the surface of the α1 domain (Lebron et al. 1998). It has been 
suggested that a complex is formed between the HFE protein and the transferrin receptor 1 (TFR1), 
which influences intracellular iron delivery (Feder et al. 1998; Parkkila et al. 1997). The binding 
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affinity of TFR1 for transferrin is greatly reduced through the complex formation with HFE (Feder 
et al. 1998, Gross et al. 1998, Ikutu et al. 2000). Due to the role of HFE in iron regulation and the 
importance of iron in the myelination process via oligodendrocytes, mutations in HFE, which alter 
the protein structure, may indirectly influence the maintenance of axons.  
 
The most common mutation found in HFE is a guanine to adenine single nucleotide polymorphism 
(SNP) in exon 4 (845 G > A, rs1800562) resulting in a substitution of tyrosine for cysteine at amino 
acid position 282 (Cys-282-Tyr, C282Y) (Feder et al. 1996). The carrier frequency of this mutation 
has been reported as approximately one in ten among individuals of Northern European decent and 
one in six in the Caucasian population of South Africa (de Villiers et al.1999b). Homozygosity (two 
copies) for the C282Y mutation occurs in approximately 1 in 100 individuals in the South African 
population compared with 1 in 200 among Europeans. Several studies have also found significant 
differences in iron status in heterozygous individuals (Adams et al. 2005; Beutler et al. 2000; 
Beutler et al. 2003; Jackson et al. 2001). Inheritance of two copies of the C282Y mutation has been 
found to result in elevated transferrin saturation levels in approximately 50% of women and 80% of 
men (Delatycki et al. 2005).  
 
It has been reported that among 1700 MS patients, no subjects with clinical HH were found 
(Valberg et al. 1989). In the study by Kotze et al. (2006), 118 patients with MS in the South African 
population were screened for the C282Y mutation. Seventeen of the MS patients included in this 
South African study were found to be heterozygous for the mutation with three having below and 
none above the reference values for transferrin saturation. One of the patients, as well as her sister 
following family screening, were furthermore found to be homozygous for the C282Y mutation in 
the presence of high iron stores, although iron deficiency was reported at an early age that required 
iron supplementation in the index case. They had no clinical manifestation of haemochromatosis 
and liver function enzymes were normal in both. These data raised the possibility that defective iron 
regulation in MS patients may be as a result of a metabolic blockage in the absorption of iron 
(Kotze et al. 2006). Most studies have found no difference in frequency of HFE between MS 
patients and the general population as also confirmed by Kotze et al. (2006).  
 
Iron metabolism is influenced by chronic inflammation, a common feature of MS. HFE mutations 
are are not considered as as a cause of MS but may serve as a marker for iron dysregulation, either 
in the presence of high or low iron stores. Similarly, mutations in the MTHFR gene do not directly 
cause MS but represent an important biomarker to assess increased need for folate and other B-
vitamins required as co-factors in the folate-homocysteine pathway. In this study the focus has 
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shifted from a one-gene-one-disease genetic testing approach to a pathology-supported genetic 
testing approach recently introduced at the Department of Pathology (Kotze et al. 2009; Schneider, 
2009), to evaluate the genetic contribution in complex, multi-factorial diseases such as MS.  
 
Pathology supported genetic testing requires that the patient‟s genetic profile be correlated with 
his/her clinical history and pathology (biochemical measurements of serum iron, homocysteine, 
etc.) to assess gene expression and response to treatment and/or lifestyle changes. Such a 
nutrigenetics approach forms an important part of personalized medicine to ensure continuous 
availability of nutrients pivotal for the biochemical pathways implicated in myelin production and 
maintenance.  
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1.11.   AIMS AND OBJECTIVES OF THIS STUDY 
 
The overall objectives of this study were to investigate the role of mutations in MTHFR and HFE in 
folate and iron metabolism, respectively, implicated in the development and/or progression of MS. 
To enable the incorporation of genetic testing as part of a comprehensive gene-based, pathology 
supported screening and intervention program aimed at improved quality of life in patients 
diagnosed with multiple sclerosis (MS), it was necessary to compare different mutation detection 
systems in terms of accuracy, sensitivity, cost effectiveness and ease of operation.  
 
The specific aims were:  
1. Standardization and optimization of Real Time Polymerase Chain Reaction (RT-PCR) 
assays to demonstrate the analytical validity of high-throughput genotyping in comparison 
with DNA sequencing as the gold standard. 
 
2. Comparison of mutation detection using three RT-PCR instruments for quality assurance 
purposes:  
 The ABI™  7900HT (Applied Biosystems®, Foster City, California, USA),  
 The Roche LightCycler® 480 II system (Roche Applied Science, Germany),  
 The Corbett Rotor-Gene™ 6000 5-plex HRM (originally Corbett Research, Australia; 
now Rotor-Gene
™
 Q, QIAGEN
®
, Germany).  
3. Screening of MS patients and controls for MTHFR and HFE mutations, and comparison 
with DNA sequencing of controls for quality assurance purposes:  
 MTHFR 1298 A>C,  
 MTHFR 677 C>T,  
 HFE 845 G>A.  
 
Ultimately, the detection of genetic variation influencing serum iron status and homocysteine levels 
would provide a scientific basis for long-term nutritional intervention in a subgroup of MS patients 
with altered nutritional requirements (nutrigenetics application).   
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2.1.  Study population  
The study population consisted of 90 patients diagnosed with MS according to MRI scans and 
clinical examination. In addition, 49 blood and saliva samples were obtained from subjects drawn 
from the same population and age group, without any signs or symptoms of MS as control subjects.  
A subset of 43 MS patients were subjected to biochemical determinations including serum iron, 
transferrin, transferrin saturation, ferritin, haemoglobin and the generally used inflammatory 
marker, C-reactive protein. Serum iron, transferrin, transferrin saturation, haemoglobin and CRP 
concentrations were determined on Siemens Advia 1800 autoanalyser and ferritin was done on 
Seimens Centaur analyser. These pathology assays were performed at the department of Chemical 
Pathology (NHLS) using standard techniques.  
 
The MS patient samples were obtained from studies previously done by Kotze et al. (2001) and an 
extention of the pilot study of van Rensburg et al. (2006), after obtaining informed consent 
(Appendix A).  Therefore no further details on the clinical characteristics of the study population 
are provided as the focus of the study was to use these DNA samples to standardize the genotype 
assays required to implement the pathology supported genetic testing approach for MS (performed 
under research protocol NO7/09/203 that includes both a research and service component).  
 
Ethical approval has been obtained from the Human Research Committee of the University of 
Stellenbosch (NO7/09/203) (Appendices B, C, D, E).  
 
 
2.2.  DNA Extraction  
 
2.2.1.  DNA Extraction from Whole Blood Using the QIAGEN Mini Kit  
For this protocol the buffy coat was used from each patient. This consisted of an initial 
centrifugation step of whole blood at 3000 rpm (revolution per minute) for 5 minutes. Subsequent 
to this step the buffy coat (middle layer consisting of white blood cells) was removed and 
transferred to a new eppendorf tube. Into a 1.5 ml microcentrifuge tube, 20 µl QIAGEN Proteinase 
K was added. Thereafter 200 µl of blood sample (buffy coat) was pipetted into the tube. From 
buffer A 200 µl was added to the mixture and was vortexed for 15 seconds to ensure efficient lysis. 
This was then incubated for 10 minutes at 56ºC, for the DNA to reach its maximum lysis. The tube 
was then centrifuged briefly for removal of drops from the inside of the lid. Addition of 200 µl of 
100% ethanol was carried out, followed by pulse-vortexing for 15 seconds. The mixture was then 
carefully applied to a QIAamp Mini spin column (2 ml collection tube) and was centrifuged at 8000 
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rpm for 1 minute. The QIAamp Mini spin column was then placed into a 2 ml collection tube. Into 
the QIAamp Mini spin column 500 µl wash buffer 1 was added which was followed by 
centrifugation at 8000 rpm for 1 minute. QIAamp Mini spin column was once more placed into 
another collection tube, which was followed by addition of 500 µl of wash buffer 2. The tube was 
then centrifuged for 3 minutes at 14000 rpm. The QIAamp Mini spin column was placed into a 
clean 1.5 ml microcentrifuge tube with addition of 100 µl buffer AE. It was then incubated at room 
temperature for 5 minutes and further centrifugation at 8000 rpm. The final solution contained 
purified DNA solution, which was put on a shaker over night. The obtained DNA solution was 
stored at 4ºC and at -20ºC for long-term use.  
 
2.2.2.  DNA Extraction from Buccal Swabs Using QIAGEN Mini Kit  
The Buccal swabs were placed into a 2 ml microcentrifuge tube and to it 600 µl PBS solution was 
added. To each tube 20 µl QIAGEN Proteinase and 400 µl buffer AL was added and mixed for 15 
seconds, by means of vortexing. The tubes were then incubated for 10 minutes at 56ºC. Brief 
centrifugation was done for removal of drops from the lid. Into a QIAamp Mini spin column in a 2 
ml collection tube, 700 µl of the swab mixture was added and centrifuged at 8000 rpm for 1 minute. 
The QIAamp Mini spin column containing the unpurified DNA was then placed into a clean 2 ml 
collection tube and the previous step was repeated. Addition of 500 µl wash buffer 1 to the QIAamp 
Mini spin column was completed. The mixture was centrifuged for 1 minute at 8000 rpm. The 
QIAamp Mini spin column was placed in a clean 2 ml collection tube and 500 µl wash buffer 2 was 
added to it which was followed by centrifugation at 14000 rpm for 3 minutes. In a 1.5 ml 
microcentrifuge tube the QIAamp Mini spin column was placed in and 150 µl of AE buffer was 
added. The solution was incubated at room temperature for 5 minutes and centrifuged at 8000 rpm 
for 2 minutes. The final solution consisted of purified DNA, which was left on the shaker overnight 
and was then stored at 4ºC and -20ºC for long-term use.  
 
2.2.3.  DNA Extraction from Whole Blood Using the QIAamp Blood Midi Kit (Spin Protocol)  
This protocol was used for purification of genomic DNA from 2 ml of whole blood.  
Into a 15 ml centrifuge tube, 200 µl of GIAGEN Protease was inserted followed by addition of 2 ml 
blood, which was mixed with the enzyme through vortexing. Buffer AL (2.4 ml) provided by the kit 
was then combined with the mixture. The vials were then inverted several times and vortexed for 
one minute. To ensure lysis the samples were incubated at 70ºC for ten minutes. Thereafter 2 ml of 
96-100% ethanol were added to the tubes and were mixed through inversion and vigorous shaking. 
Half of the mixture was then transferred onto the QIAamp Midi column placed in a 15 ml 
centrifuge tube. Centrifugation was done at 3000 rpm (1850 x g) for three minutes. The filtrates 
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were then discarded and the remainder of the solutions was loaded on the column and was 
centrifuged for three minutes at 3000 rpm (1850 x g (times gravitational acceleration)). Wash steps 
of the genomic DNA were then carried out through addition of 2 ml Buffer AW1 to the column and 
centrifugation for 5000 rpm (4500 x g) for one minute. AW2 (2 ml) was then added and centrifuged 
for 15 minutes at 5000 rpm (4500 x g). The column was then placed in a clean 15 ml centrifuge 
tube and the collection tube containing the filtrate was discarded. Nuclease free water (300 µl) was 
then added directly onto the membrane of the column, followed by five minutes incubation at room 
temperature and two minutes centrifugation at 5000 rpm (4500 x g). In order to obtain maximum 
concentration the eluate containing the DNA was reloaded onto the column and was incubated at 
room temperature for five to ten minutes. Additional centrifugation was carried out for two minutes 
at 5000 rpm (4500 x g). The solution containing purified genomic DNA was then incubated on a 
shaker at room temperature overnight to ensure even distribution of the DNA in the buffer.  
 
2.2.4.  DNA Extraction from saliva using Oragene DNA / Saliva Kit  
The saliva samples were collected in the Oragene DNA vial containing Oragene DNA solution, 
which allowed for stabilization of the collected DNA samples (2 ml). 
The Oragene DNA/saliva samples in the Oragene vial were then mixed thoroughly by inversion for 
a few seconds. The samples were incubated at 50ºC for two hours in an air incubator. Thereafter 
500 l of the mixture was transferred to a 1.5 ml microcentrifuge tube. Oragene DNA purifier (OG-
L2P, supplied) was added to the microcentrifuge tube and was mixed by vortexing for a few 
seconds that followed ten minutes incubation on ice. The centrifugation step was carried out at 
room temperature at 13000 rpm (15000 x g) for five minutes, which resulted in the separation of the 
supernatant from the pellet containing impurities, and was then transferred into a new 
microcentrifuge tube. To the tube, 500 l of 95-100% ethanol was added which was mixed 
thoroughly by inversion. The samples were incubated at room temperature for ten minutes to allow 
for DNA precipitation. The tubes were placed in the centrifuge in a known orientation (in order to 
position the pellet at the tip of the tube below the hinge as the DNA pellet will be invisible) and 
were spun for two minutes at 13000 rpm (15000 x g). The supernatant was carefully removed and 
discarded from the acquired pellet containing the DNA. An ethanol wash step was carried out by 
addition of 250 l of 70% ethanol and incubation at room temperature for one minute, after which 
the ethanol was removed completely without disturbing the pellet. Nuclease-free water (100 l) was 
then used to dissolve the DNA pellet through five seconds of vortexing. Additional vigorous 
pipetting and vortexing as well as overnight incubation on a shaker (room temperature) followed, to 
ensure that the obtained DNA sample is evenly distributed in the buffer.  
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2.3.  DNA Quantification  
Nanodrop ND-1000 Spectrophotometer (Nanodrop Technologies, USA) using v 3.5.2 software 
package was applied for detection of DNA quality and quantity. All Genomic DNA samples were 
diluted to final concentration of 10 ng/l using nuclease free water. The ratio absorbance reading at 
260/280 for all the samples ranged from 1.6 to 1.9. Any values within this range indicate absence of 
contaminants such as salts or phenols in a sample (www.nanodrop.com/techsupport/nd-1000-users-
manual.pdf).  
 
 
2.4.  Polymerase Chain Reaction (PCR) Amplification  
 
2.4.1.  Oligonucleotide Primers  
Oligonucleotide primers and probes were designed to screen specific exonic regions of MTHFR 
(see figure 2.1 MTHFR 677 C>T and figure 2.2 for MTHFR 1298 A>C) and HFE (see figure 2.3) 
using the LightCycler

 Probe Design Software 2.0 (Version 1.0. R.36). The reference sequences 
were obtained from the National Centre of Biotechnology (NCBI, www.ncbi.nlm.nih.gov) for 
MTHFR (NG_013351.1) and HFE (NM_000410). The primers and probes used in the RT-PCR 
experiments with the Roche LightCycler
®
 480 II system are specified in table 2.1.  
 
 
5’ 10814 – 15120 3’ 
GGAGGCTTCAACTACGCAGTGGACCTGGTGAAGCACATCCGAAGTGAGTTTGGTGAC
TACTT...tccctgtggtctcttcatccctcgccttgaacaggtggaggccagcctctcctgactgtcatccctattggcagGTTACCCC
AAAGGCCACCCCGAAGCAGGGAGCTTTGAGGCTGACCTGAAGCACTTGAAGGAGAAG
GTGTCTGCGGGAGCCGATTTCATCATCACGCAGCTTTTCTTTGAGGCTGACACATT
CTTCCGCTTTGTGAAGGCATGCACCGACATGGGCATCACTTGCCCCATCGTCCCCGG
GATCTTTCCCATCCAGgtgaggggcccaggagagcccataagctccctccaccccactctcaccgcaccgtcctcgcacaggc
tgggggctctgggtggagtgctgagttcgctgagttcttcccagatctcctctcaggtccagaacttgcacagcgttgcttggccaccccattttgg
ttacctctaattttccccccaaaacccagcaacagtgtctgttgaggggtttgttgta 
 
Figure 2.1. MTHFR reference sequence with the forward and reverse primers highlighted in blue 
for MTHFR 677 C>T. Fluorescein-bound Probe 1 is highlighted in green and the LC-Red-460-
bound Probe 2 highlighted in red. The red “C” indicates the position of the SNP. The bases in 
uppercase indicate exonic regions with the lower case representative of intronic regions. 
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5’ 16381 – 17010 3’ 
ggcctgcagaccttccttgcaaatacatctttgttcttgggagcgggagggcagaagaagtttgcatgcttgtggttgacctgggaggagtcagg
ggcagaatttacaggaatggcctcctgggcatgtggtggcactgccctctgtcaggagtgtgccctgacctctgggcacccctctgccagGG
GCAATTCCTCTTCCCCTGCCTTTGGGGAGCTGAAGGACTACTACCTCTTCTACCTGAA
GAGCAAGTCCCCCAAGGAGGAGCTGCTGAAGATGTGGGGGGAGGAGCTGACCAGTGA
AGAAAGTGTCTTTGAAGTCTTCGTTCTTTACCTCTCGGGAGAACCAAACCGGAAT
GGTCACAAAgtgagtgatgctggagtggggaccctggttcatcccctgcccctggcctgaccccagctgcaggccaggctgcgggg
ctgtgacttccccatcctgtgccctcccctccatgctgtggacatggcaaagggagaagggtaagttgggagacctccacctggaagggcttag
ggaggcaaagacaggctgggtctttgttgggggccgtgagagggactcagggtgccaaacctgatggtcgccccagccagctcaccgtctcc 
 
Figure 2.2. MTHFR reference sequence with the forward and reverse primers for MTHFR 1298 
A>C highlighted in blue. Fluorescein-bound Probe 1 and LC-Red-460-bound Probe 2 highlighted in 
green and red, respectively. The red “A” indicates the position of the SNP.The bases in uppercase 
indicate exonic regions with the lower case representing intronic regions. 
 
 
 
5’ 10361 – 10990 3’  
GgtaaacagatcccctctcctcatccttcctctttcctgtcaagtgcctcctttggtgaaggtgacacatcatgTGACCTCTTCAGTGA
CCACTCTACGGTGTCGGGCCTTGAACTACTACCCCCAGAACATCACCATGAAGTGGCG
AAGGATAAGCAGCCAATGGATGCCAAGGAGTTCGAACCTAAAGACGTATTGCCCAATG
GGATGGGACCTACCAGGGCTGGATAACCTTGGCTGTACCCCCTGGGGAAGAGCAGA
GATATACGTGCCAGGTGGAGCACCCAGGCCTGGATCAGCCCCTCATTGTGATCTGG
Ggtatgtgactgatgagagccaggagctgagaaaatctattgggggttgagaggagtgcctgaggaggtaattatggcagtgagatgaggat
ctgctctttgttagggggtgggctgagggtggcaatcaaaggctttaacttgctttttctgttttagAGCCCTCACCGTCTGGCAC
CCTAGTCATTGGAGTCATCAGTGGAATTGCTGTTTTTGTCGTCATCTTGTTCATTGGAAT
TTTGTTCATAATATTAAGGAAGAGGCAGGGTTCAAgtgagtaggaacaagggggaagtctcttagtacctctg 
 
Figure 2.3. HFE reference sequence illustrating the alignment of the forward and reverse primers 
for HFE 845 G>A highlighted in blue. LC-Red-640-bound Probe 1 is highlighted in red and 
Fluorescein-bound Probe 2 highlighted in green. The yellow “G” indicates the position of the 
SNP.The bases in uppercase indicate exonic regions with the lower case representing intronic 
regions.  
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Table 2.1. Details of the custom-designed Roche primers and HybProbe probes used in the RT-
PCR.  
MTHFR 677 C>T 
Forward Primer 5' Pos 3' Pos Length GC% Tm Conc 
CGAAGTGAGTTTGGTGACTAC 731 751 21 47.6 59.1 0.5 
Reverse Primer 5' Pos 3' Pos Length GC% Tm Conc 
CAAGTGATGCCCATGTCG 933 916 18 55.6 59.2 0.5 
Probe 1 5' Pos 3' Pos Length GC% Tm Conc 
GAGCCGATTTCATCATCACGCAGC-
Fluorescein 
846 869 24 54.2 65.2 0.2 
Probe 2 5' Pos 3' Pos Length GC% Tm Conc 
LC Red640-
TTCTTTGAGGCTGACACATTCTTCCGCTTT
G-Phosphate 
872 902 31 45.2 68.1 0.2 
MTHFR 1298 A>C 
Forward Primer 5' Pos 3' Pos Length GC% Tm Conc 
GCTGAAGGACTACTACCTCTTCTA 1381 1404 24 45.8 60.1 0.5 
Reverse Primer 5' Pos 3' Pos Length GC% Tm Conc 
CACTTTGTGACCATTCCG 1534 1517 18 50 59.8 0.5 
Probe 1 5' Pos 3' Pos Length GC% Tm Conc 
CCAGTGAAGCAAGTGTCTTTGAAGTC-
Fluorescein 
1461 1486 26 46.2 64.8 0.2 
Probe 2 5' Pos 3' Pos Length GC% Tm Conc 
LC Red 640-
CGTTCTTTACCTCTCGGGAGAACCAAAC-
Phosphate 
1489 1516 28 50 68.3 0.2 
HFE 845 G>A  
Forward Primer 5' Pos 3' Pos Length GC% Tm Conc 
GGCTGGATAACCTTGGCTGTA 10584 10604 21 52.4 60 0.5 
Reverse Primer 5' Pos 3' Pos Length GC% Tm Conc 
CTCAGGCACTCCTCTCAAC 10743 10725 19 57.9 60.1 0.5 
Probe 1 5' Pos 3' Pos Length GC% Tm Conc 
LC Red 640-
CTGGCACGTATATCTCTGCTCTTCCC-
Phosphate 
10637 10612 26 53.8 65.2 0.2 
Probe 2 5' Pos 3' Pos Length GC% Tm Conc 
CTGATCCAGGCCTGGGTGCTCC-Fluorescein 10661 10640 22 68.2 68.3 0.2 
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2.4.2.  PCR Reaction Mixture and Thermal Cycling Parameters  
PCR was performed in 50 µl reactions, using a commercially available Kit from Promega (GoTaq
®
 
Flexi DNA Polymerase PCR). Each reaction mixture contained 1 µl of 200 ng template DNA, 0.2 
mM of each deoxyribonucleotide triphosphate (dNTP) (Fermentas), 10 µl GoTaq Flexi Buffer, 1.5 
mM magnesium chloride (MgCl2), 60 pmol of each primers, 1.25 U GoTaq
® 
polymerase.  
The amplification of target sequences was performed using Applied Biosystems
®
 2720 PCR 
instruments. The PCR procedure exemplified an initial denaturation step at 95ºC for 5 minutes. 
Followed by 40 cycles of denaturation at 94ºC for 30 seconds, annealing of 55.5ºC for 30 seconds 
and a 2 minutes extension at 72ºC, which continued with a final extension period at 72ºC for 10 
minutes.  
 
2.5.  Gel Electrophoresis  
Electrophoresis was carried out using a 2% (w/v) agarose gel consisting of 2.0 g agarose and 100 
ml 1x TBE Buffer (90 mM Tris-HCl, 90 mM boric acid [H3BO3] and 2.2 mM EDTA [pH 8.0]).  
Each PCR product (3 µl) was mixed with 5 µl blue Loading Dye (consisting of 15% Ficoll
®
 400, 
0.03% bromophenol blue, 0.03% xylene cyanol FF, 0.4% orange G, 10 mM Tris-HCl (pH 7.5) and 
50 mM EDTA) and was loaded onto the gel. Gel electrophoresis was then run at 100 V for 1 hour in 
electrophoresis buffer (80 ul EtBr in 800 ml 1x TBE).  A 1 Kb DNA Ladder (Promega) was used to 
determine the fragment size of each PCR fragment. Each fragment on the gel was visualized using 
an ultraviolet light transilluminator (TFX-35M Life Technologies, GIBRO BRL).  
 
2.6.  DNA Sequencing  
PCR products obtained for the HFE 845 G>A and MTHFR 677 C>T SNPs were sent for post-PCR 
clean-up as well as automated sequencing at the DNA Sequencing Central facility of Stellenbosch 
University.  
Sequencing of the control samples for the MTHFR 1298 A>C SNP were sent to Inqaba 
Biotechnical Industries (Pty) Ltd for post PCR clean up for sequencing and automated sequencing.  
 
2.7.  Bioinformatics and Sequence Analysis  
In order to analyze the sequences obtained using conventional PCR, Staden package was used, 
which consisted of wide variety of functions for sequence manipulation and interpretation. The 
software consists of a series of tools that are particularly flexible for DNA sequence preparation 
(pregap4), assembly (gap4), editing (gap4) and DNA/protein sequence analysis (spin). In this study 
Pregap4 was used which is a tool applied for pre-processing sequencing chromatogram files (such 
as ABI files). The Pregap4 allowed for sequence format conversions, quality assessment, repeat and 
Chapter Two: Detailed Experimental Procedures 
 
31 
contaminant screening and interfaces. The Gap4 program was used for sequence assembly and 
editing. This program also presented Bayesian consensus algorithm. Several graphical display links 
was offered by this software, which facilitated the assembly to be viewed at different levels of 
detail. Estimate base accuracies, which use phred base quality values, aided in calculating the 
quality of the consensus sequence. Other configuring modules such as trace format conversion, 
quality clip and Gap4 shot-gun assembly was used. Window length average confidence of 3‟ and 5‟ 
numbers of uncalled bases, as well as minimum exact match, maximum percentage mismatch, 
maximum consensus length and database size could be configured. This assisted in parts of 
assembly that required editing or extra data to be easily found and as a result rapid finishing and 
consensus of known accuracy could be achieved. 
 
The application of this software assigned for viewing the nucleotide sequence of the subjects. In 
addition, the target sequence could be directly compared to the reference sequence (www-
bimas.cit.nih.gov/molbio/readseq), for detection of mutations viewed in different colour 
presentation of that specific nucleotide base change. Bayesian consensus algorithm offered a 
graphical representation of the nucleotides peaks and allocation of the mutations found.  
 
2.8.  Real-Time Polymerase Chain Reaction (RT-PCR)  
 
2.8.1.  Applied Biosystems
®
 TaqMan
®
 SNP Genotyping with the 7900HT  
ABI
™
 TaqMan
® 
SNP Genotyping assays are standardised mixtures that consist of unlabelled 
primers and TaqMan
®
 MGB probes (FAM
™
 and VIC
® 
dye-labelled). The pre-designed assays are 
suitable for end-point genotyping by allelic discrimination analysis for SNPs. The assays employed 
in this study were MTHFR 677 C>T (C_1202883_20, rs1801133), MTHFR 1298 A>C 
(C_850486_20, rs1801131) and HFE 845 G>A (C_1085595_10, rs1800562).  
 
The 40X TaqMan
® 
assay was diluted to 20X in sterile SABAX water (double distilled water). The 
components of a 20 l reaction were: 20 ng/l of template DNA (2.0 l), 10 l of TaqMan® 
Universal PCR Master Mix (P/N 4304437), 20X TaqMan
® 
SNP Genotyping Assay (1.0 l) and 7.0 
l SABAX double distilled water (table 2.2). The amplification was carried out with a three-step 
thermal cycling program consisting of an initial hold step at 95C for 10 minutes, 45 cycles of 
denaturation at 92C for 15 seconds and annealing/extension at 60C for 1 minute (table 2.3), 
followed by allelic discrimination run. 
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Table 2.2. ABI
™
 Allelic Discrimination PCR Reaction 
Reaction Components 
Volume/Well 
(5 μl Vol rxn) 
Volume/Well 
(20 μl Vol rxn) 
Final 
Concentration 
TaqMan Universal PCR 
Master Mix (10X) 2.5 10 1X 
20X TaqMan SNP 
Genotyping Assay Mix 0.25 1 1X 
Nuclease Free Water 0.25 7   
Genomic DNA 2 2   
Total 5 20   
 
Table 2.3. ABI
™
 Thermal Cycling Conditions 
Times and Temperatures 
Initial 
Steps 
Denaturation Anneal/Extend 
Hold 40 cycles 
10 min 
95˚C 
15 sec 92˚C 1 min 60˚C 
 
 
2.8.2.  Corbett Rotor-Gene 6000 / QIAGEN Rotor-Gene Q  
Rotor-Gene 6000 series Multiplexing System, 5-Plex HRM model (Corbett Research, Australia) 
was used with ABI™ TaqMan® SNP Genotyping Assays. Mutation detection using this system is 
achieved by allelic discrimination and scatterplot analysis of the fluorescence data obtained from 
the RT PCR run. Individual reactions with a total volume of 10 ul consisted of TaqMan
®
 Universal 
PCR Master Mix (5 l), 20X TaqMan® SNP Genotyping assay (0.5 l), double-distilled water (3.5 
l) and 1 l of template DNA (10 ng/l). This reaction mixture was used for all the samples 
analysed with this instrument. Thermal Cycling parameters used included a 45 cycle repeat of initial 
hold step for 10 minutes at 95C, denaturation at 92C for 15 seconds and an annealing/final 
extension step for 1 minute at 60C with the set channel (Green / FAM™ dye and Yellow / VIC® 
dye) to acquire at the end of the cycling step.  
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2.8.3.  Roche LightCycler
®
 480 II  
LightCycler
®
 480 mix, consisting of custom designed primers and probes (HybProbes probes) and 
LightCycler
®
 480 Genotyping Master was applied for amplification of target DNA as well as SNP 
analysis using melting curves. The 20 l reaction mixture was prepared containing 5 l of 10 ng/l 
template DNA, in addition to 9 l PCR grade water (nuclease free), 1 l of the primer set (0.5 M 
each), 1l HybProbe probes (0.2 M each) and 4 l of 5x concentration LightCycler 480 
Genotyping Master. LightCycler
®
 480 II, 96 well plate was set up with the total of 20 l reaction 
volume per well accordingly. The thermal cycling program applied for genotyping with mono-
colour HybProbe probe is listed in table 2.4.  
 
Table 2.4. RT-PCR protocol for the Roche LightCycler
®
 480 II system using 96 well plates. 
Programs 
Program Name Cycles Analysis Mode   
Pre-Incubation 1 None   
Amplification 45 Quantification   
Melting Curve 1 Melting Curves   
Cooling 1 None   
Target °C 
Acquisition 
Mode 
Hold 
(hh:mm:ss) 
Ramp Rate 
(°C/s) 
Acquisitions 
(per °C) 
PreIncubation 
95 None 00:10:00 4.4 
_
 
Amplification 
95 None 00:00:10 4.4 
_
 
Primer 
Dependent* 
Single 00:00:10 2.2 
_
 
72 None 00:00:10 4.4 
_
 
Melting Curve 
95 None 00:01:00 4.4 
_
 
40 None 00:02:00 1.5 
_
 
75 Continuous 
_
 
_
 6 
Cooling 
40 None 00:00:30 1.5 
_
 
* Annealing temperature: MTHFR 1298 A>C = 52ºC, MTHFR 677 C>T = Variable, HFE 845 G>A 
= Variable. 
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2.9  Statistical Analysis  
All data were analysed by a professional statistician affiliated with the Department of Pathology, 
using StatSoft
®
 STATISTICA version 6. One-Way ANOVA, Bonferroni was used to analyse for 
statistically significant differences between dependent numerical variables of iron (transferrin, 
percentage transferrin saturation, ferritin, serum iron levels) and the independent genotype variables 
for MTHFR 677 C>T, MTHFR 1298 A>C and HFE 845 G>A. This test uses mean and standard 
deviation to calculate significant differences and was selected due to its ability to analyse designs 
with a single categorical independent variable.  
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The procedures described below were performed in 90 patients diagnosed with MS according to 
MRI scans and clinical examination and 49 control samples. The MS patient samples were obtained 
from studies previously done by Kotze et al. (2001) and van Rensburg et al. (2006), after obtaining 
informed consent (Appendix A). No further details on the clinical characteristics of the study 
population are provided as the focus of the study was to use these DNA samples to standardize the 
genotype assays required to implement the pathology supported genetic testing approach for MS 
(performed under research protocol NO7/09/203 that includes both a research and service 
component). Conventional sequencing was perfomed for MTHFR 677 C>T, MTHFR 1298 A>C 
and HFE 845 G>A, using random selection of samples. This was done to verify the results obtained 
from the RT-PCR runs. Due to the random nature of the selection process, not all genotypes are 
represented in the conventional sequencing results.  
 
3.1.  Conventional Sequencing – Gels and Electropherograms  
The PCR products obtained with the MTHFR 677 C>T conventional primers were visualized with 
ethidium bromide in a 2% agarose gel, presented in figure 3.1.1. The sequencing results are 
presented as electropherograms for each control sample in figures 3.1.2, 3.1.3 and 3.1.4. Forward 
and reverse sequencing reactions were carried out, with either included here in a randomized 
manner to further reduce selection bias and emphasize the analytic validity of the genotyping.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1.1. A 2% (w/v) agarose gel visualized with 0.0001% (v/v) ethidium bromide (EtBr). 
Lanes 1, 2 and 3 contain amplicons of 256 bp, using MTHFR 677 C>T-primer set. Lane 4 contains 
the NTC (Non-Template Control) PCR reaction product.  
Abbreviations: bp = base pairs. 
 
 
 
1       2       3      4      
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Figure 3.1.3. Electropherogram depicting the forward (sense) sequencing reaction of an amplified 
PCR product obtained with the MTHFR 677 C>T primer set. The arrow indicates the SNP position.  
The *Y* at the indicated position corresponds to a genotype of CT, which signifies a Heterozygote. 
 
 
 
 
 
 
 
Figure 3.1.2. Electropherogram depicting the reverse (anti-sense) sequencing reaction of an 
amplified PCR product obtained with the MTHFR 677 C>T primer set. The arrow indicates the 
SNP position. The *R* at the indicated position corresponds to a genotype of GA, which signifies a 
Heterozygote. 
 
 
 
 
 
 
 
Figure 3.1.4. Electropherogram depicting the forward (sense) sequencing reaction of an amplified 
PCR product obtained with the MTHFR 677 C>T primer set. The arrow indicates the SNP position. 
The *C* at the indicated position corresponds to a genotype of CC, which signifies a Wild Type 
genotype. 
 
 
The PCR products obtained with the MTHFR 1298 A>C conventional primers were visualized with 
ethidium bromide in a 2% agarose gel, presented in figure 3.1.5. The sequencing results are 
presented as electropherograms for each control sample in figures 3.1.6, 3.1.7 and 3.1.8. Forward 
and reverse sequencing reactions were carried out, with either included here in a randomized 
manner to further reduce selection bias and emphasize the analytical validity of the genotyping.  
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Figure 3.1.5. A 2% (w/v) agarose gel visualized with 0.0001% (v/v) ethidium bromide (EtBr). 
Lanes 1, 2 and 3 contain amplicons of 465 bp, using MTHFR 1298 A>C-primer set. Lane 4 contains 
the NTC (Non-Template Control) PCR reaction product.  
Abbreviations: bp = base pairs. 
 
 
 
 
 
 
 
Figure 3.1.6. Electropherogram depicting the reverse (anti-sense) sequencing reaction of an 
amplified PCR product obtained with the MTHFR 1298 A>C primer set. The arrow indicates the 
SNP position. The *K* at the indicated position corresponds to a genotype of AC, which signifies a 
Heterozygous genotype. 
 
 
 
 
 
 
 
Figure 3.1.7. Electropherogram depicting the reverse (anti-sense) sequencing reaction of an 
amplified PCR product obtained with the MTHFR 1298 A>C primer set. The arrow indicates the 
SNP position. The *G* at the indicated position corresponds to a genotype of GG, which signifies a 
Homozygous genotype. 
 
1        2        3        4    
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Figure 3.1.8. Electropherogram depicting the reverse (anti-sense) sequencing reaction of an 
amplified PCR product obtained with the MTHFR 1298 A>C primer set. The arrow indicates the 
SNP position. The *T* at the indicated position corresponds to a genotype of TT, which signifies a 
Wild Type genotype. 
 
 
The PCR products obtained with the HFE 845 G>A conventional primers were visualized with 
ethidium bromide in a 2% agarose gel, presented in figure 3.1.9. The sequencing results are 
presented as electropherograms for each control sample in figures 3.1.10, 3.1.11 and 3.1.12. 
Forward and reverse sequencing reactions were carried out, with either included here in a 
randomized manner to further reduce selection bias and emphasize the validity of the genotyping.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1.9. A 2% (w/v) agarose gel visualized with 0.0001% (v/v) ethidium bromide (EtBr). 
Lanes 1, 2 and 3 contain amplicons of 465 bp, using HFE 845 G>A-primer set. Lane 4 contains the 
NTC (Non-Template Control) PCR reaction product.  
Abbreviations: bp = base pairs.  
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Figure 3.1.10. Electropherogram depicting the forward (sense) sequencing reaction of an amplified 
PCR product obtained with the HFE 845 G>A primer set. The arrow indicates the SNP position. 
The *G* at the indicated position corresponds to a genotype of GG, which signifies a Wild Type 
genotype.  
 
 
 
 
 
 
 
 
 
 
Figure 3.1.11. Electropherogram depicting the forward (sense) sequencing reaction of an amplified 
PCR product obtained with the HFE 845 G>A primer set. The arrow indicates the SNP position. 
The *G* at the indicated position corresponds to a genotype of GG, which signifies a Wild Type 
genotype. 
 
 
 
 
 
 
 
 
Figure 3.1.12. Electropherogram depicting the forward (sense) sequencing reaction of an amplified 
PCR product obtained with the HFE 845 G>A primer set. The arrow indicates the SNP position. 
The *G* at the indicated position corresponds to a genotype of GG, which signifies a Wild Type 
genotype. 
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3.2.  ABI

 7900HT  
 
The ABI™ 7900HT was used with ABI™ TaqMan® SNP Genotyping assays in this investigation. 
Each 96 well plate contained MS DNA samples (10 ng/l) with unknown genotypes, 12 NTCs with 
nuclease free water (strongly recommended by ABI
™
) and four DNA controls with known 
genotypes determined by conventional PCR and DNA sequencing prior to the RT PCR run. An 
amplification run using the Standard Curve (AQ) setting was performed, during which amplicons 
are exponentially synthesized and the associated fluorescence plotted as a graph by the ABI
™
 SDS 
software package (version 2.3) displaying “ΔRn (unit of fluorescence) versus cycles.” Thereafter, a 
post-amplification scan with the allelic discrimination setting was done and the SDS software 
presents the results on an allelic discrimination scatterplot by contrasting the reporter fluorescence. 
After signal normalization and multi-component analysis, the software plots the data obtained from 
a well as a single data-point on the scatterplot. The allelic discrimination analysis displays the 
results as an “Allele Y (Al 2) versus Allele X (Al 1)” graph.  
 
All three assays (MTHFR 677 C>T, MTHFR 1298 A>C and HFE 845 G>A) ran on the ABI 
7900HT were successful, yielding clear amplification of the polymorphic target sequence as well as 
precise genotype calling for each sample. This was further verified by the internal controls loaded 
on each plate, matching the DNA sequencing data. In addition, the NTCs revealed clear clustering 
per plate with absence of both alleles in the amplification and allelic discrimination analysis, 
corresponding to the absence of contamination in the procedure. The results obtained were then 
used in the statistical analysis.  
 
The investigation of MTHFR 677 C>T in two sample batches yielded the amplification graphs 
presented in figures 3.2.1 (sample batch one) and 3.2.3 (sample batch two). These graphs illustrate 
successful amplification and fluorescence by the ABI
™
 TaqMan
®
 SNP Genotyping assay. The 
allelic discrimination scatterplots depicted in figures 3.2.2 (sample batch one) and 3.2.4 (sample 
batch two) clearly indicate the different genotype groups with wild types represented as red dots, 
heterozygotes in green, homozygotes in blue and NTCs in black.  
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Figure 3.2.1. Amplification achieved in sample batch one using the ABI 
TaqMan
®
 MTHFR 677 C>T assay (ΔRn vs number of cycles). The threshold level 
is set at 1. ΔRn = unit of fluorescence. Figure 3.2.2. Allelic Discrimination Analysis for sample batch one 
using the ABI TaqMan® MTHFR 677 C>T assay (Y (C_1202883_20-
A) vs Allele X (C_1202883_20-G)). Black = NTC, Red = Wild type, 
Green = Heterozygous, Blue = Homozygous. 
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Figure 3.2.4. Allelic Discrimination Analysis for sample batch two 
using the ABI TaqMan® MTHFR 677 C>T assay (Allele Y 
(C_1202883_20-A) vs Allele X (C_1202883_20-G)). Black = NTC, 
Red = Wild type, Green = Heterozygous, Blue = Homozygous. 
Figure 3.2.3. Amplification achieved in sample batch two using the ABI 
TaqMan
®
 MTHFR 677 C>T assay (ΔRn vs number of cycles). The threshold level 
is set at 1. ΔRn = unit of fluorescence. 
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The genotype distribution observed for MTHFR 677 C>T achieved through application of the 
ABI™ 7900HT system is presented in figure 3.2.5 and represents the combined frequencies for 
both sample batches. The total study population, which includes MS samples and controls, was 
found to consist of 51.82% wild type, 32.85% heterozygotes, 8.76% homozygotes and 6.57% were 
undetermined.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The investigation of MTHFR 1298 A>C in two sample batches yielded the amplification graphs 
presented in figures 3.2.6 (sample batch one) and 3.2.8 (sample batch two). These graphs illustrate 
successful amplification and fluorescence by the ABI
™
 TaqMan
®
 SNP Genotyping assay. The 
allelic discrimination scatterplots depicted in figures 3.2.7 (sample batch one) and 3.2.9 (sample 
batch two) clearly indicate the different genotype groups with wild type represented as red dots, 
heterozygotes in green, homozygotes in blue and NTCs in black. 
Figure 3.2.5. Genotype distribution of 139 samples obtained using the 
ABI TaqMan® MTHFR 677 C>T assay. 90 MS patient samples (in 
blue) presented with 44 wild type (49%), 29 heterozygotes (32%), 9 
(10%) homozygotes and 8 (9%) undetermined genotypes. Among the 
49 control samples (in red), 27 (57%) were wild type, 16 (34%) 
heterozygotes, 3 (6%) homozygotes and 1 (2%) was undetermined. 
 
Chapter Three: Results 
 
45 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.6. Amplification achieved in sample batch one using the ABI TaqMan® 
MTHFR 1298 A>C assay (ΔRn vs number of cycles). The threshold level is set at 
0,7. ΔRn = unit of fluorescence. Figure 3.2.7. Allelic Discrimination Analysis for sample batch one 
using the ABI TaqMan® MTHFR 1298 A>C assay (Allele Y 
(C_850486_20-T) vs Allele X (C_850486_20-G)). Black = NTC, Red 
= Wild type, Green = Heterozygous, Blue = Homozygous. 
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Figure 3.2.9. Allelic Discrimination Analysis for sample batch two 
using the ABI TaqMan® MTHFR 1298 A>C assay (Allele Y 
(C_850486_20-T) vs Allele X (C_850486_20-G)). Black = NTC, Red 
= Wild type, Green = Heterozygous, Blue = Homozygous. 
Figure 3.2.8. Amplification achieved in sample batch two using the ABI 
TaqMan
®
 MTHFR 1298 A>C assay (ΔRn vs number of cycles). The threshold level 
is set at 0,7. ΔRn = unit of fluorescence. 
Chapter Three: Results 
 
47 
The genotype distribution observed for MTHFR 1298 A>C achieved through application of the 
ABI 7900HT system is presented in figure 3.2.10 and represents the combined frequencies for 
both sample batches. The total study population, which includes MS samples and controls, was 
found to consist of 45.32% wild type, 41.01% heterozygotes, 4.32% homozygotes and 9.35% were 
undetermined. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The investigation of HFE 845 G>A in two sample batches yielded the amplification graphs 
presented in figures 3.2.11 (sample batch one) and 3.2.13 (sample batch two). These graphs 
illustrate successful amplification and fluorescence by the ABI
™
 TaqMan
®
 SNP Genotyping assay. 
The allelic discrimination scatterplots depicted in figures 3.2.12 (sample batch one) and 3.2.14 
(sample batch two) clearly indicate the different genotype groups with wild types represented as red 
dots, heterozygotes in green, homozygotes in blue and NTCs in black.  
Figure 3.2.10. Genotype distribution of 139 samples obtained using 
the ABI TaqMan® MTHFR 1298 A>C assay. 90 MS patient samples 
(in blue) presented with 45 (50%) wild type, 34 (37.78%) 
heterozygotes and 4 (4.44%) homozygotes and 7 (7.78%) 
undetermined genotypes. Among the 49 control samples (in red), 18 
(36.73%) were wild type, 23 (46.94%) heterozygotes, 2 (4.08%) 
homozygotes and 6 (12.24%) were undetermined. 
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Figure 3.2.11. Amplification achieved in sample batch one using the ABI 
TaqMan
®
 HFE 845 G>A assay (ΔRn vs number of cycles). The threshold level is 
set at 0,5. ΔRn = unit of fluorescence. Figure 3.2.12. Allelic Discrimination Analysis for sample batch one 
using the ABI TaqMan® HFE 845 G>A assay (Allele Y 
(C_1085595_10-A) vs Allele X (C_1085595_10-G)). Black = NTC, 
Red = Wild type, Green = Heterozygous. 
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Figure 3.2.13. Amplification achieved in sample batch one using the ABI 
TaqMan
®
 HFE 845 G>A assay (ΔRn vs number of cycles). The threshold level is 
set at 0,5. ΔRn = unit of fluorescence. Figure 3.2.14. Allelic discrimination analysis for sample batch two 
using the ABI TaqMan® HFE 845 G>A assay (Allele Y 
(C_1085595_10-A) vs Allele X (C_1085595_10-G)). Black = NTC, 
Red = Wild type, Green = Heterozygous, Blue = Homozygous. 
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The genotype distribution observed for HFE 845 G>A achieved through application of the ABI 
7900HT system is presented in figure 3.2.15 and represents the combined frequencies for both 
sample batches. The total study population, which includes MS samples and controls, was found to 
consist of 71.94% wild type, 17.99% heterozygotes, 1.44% homozygotes and 8.63% were 
undetermined.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.15. Genotype distribution of 139 samples obtained using the 
ABI TaqMan® HFE 845 G>A assay. 90 MS patient samples (in blue) 
presented with 62 (69%) wild type, 18 (20%) heterozygotes, no 
homozygotes and 10 (11%) undetermined genotypes. 38 (78%) wild 
type were observed among the 49 control samples (in red), 7 (14%) 
heterozygotes, 2 (4%) homozygotes and 2 (4%) were undetermined. 
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3.3. Corbett Rotor-Gene

 6000 / QIAGEN Rotor-Gene Q  
 
In this study, the Corbett Research Rotor-Gene
™
 6000 Series Multiplexing System (5-Plex HRM 
model) and the ABI TaqMan
®
 SNP Genotyping assays were applied using Allelic Discrimination 
and Scatterplot analysis for amplification and genotyping. A total of 17 MS samples, 6 controls and 
1 None Template Control (NTC) were used for each assay. This test run was to allow for the 
optimization of the assays, ensure specific binding of the primers and probes, verify amplification 
of the target sequence, evaluates fluorescence detection of the probes and precision in data acquired 
by the instrument.  
 
Allelic Discrimination analysis was applied which uses real-time kinetic data from two or more 
channels to allow genotyping of the samples. ABI™ TaqMan® Genotyping Assays consists of 
unlabeled primers used for amplification of the target sequence and TaqMan
®
 MGB Probes, FAM
™ 
 
and VIC
® 
dyes used in allelic discrimination detection. These probes are labelled with different 
fluorophores acting as a reporter dye. FAM™ and VIC fluorescence dyes are allele specific 
employed to differentiate between wild type and mutant form of each SNPs under investigation. For 
this reason, the green sensor channel was employed for detection of the FAM™ fluorescence with 
excitation wavelength of 470 nm and emission wavelength of 510 nm by the Rotor-Gene
™ 
fluorometer and the yellow channel for detection of the VIC

 fluorescence with excitation 
wavelength of 530 nm and emission wavelength of 555 nm, respectively.  
 
The allelic discrimination analysis for the MTHFR 677 C>T assay is presented in figure 3.3.1 with 
the legend and genotypes illustrated by table 3.3.1. The lines with intermittent circles represent the 
wild type (C) allele, which is detected by VIC
®
-labelled probes, while the lines without intermittent 
circles signify the homozygous (T) allele detected by FAM
™
-labelled probes. Amplification of both 
alleles indicated through significant (i.e. above the threshold level) fluorescence of both dyes 
represents the heterozygous (CT) state. The indicated threshold level (0.1) is a discriminatory 
parameter employed during analysis which determines the difference between a positive and 
negative amplification reading. Fluorescence readings above the threshold indicate the presence of a 
specific allele.  
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Figure 3.3.1. Allelic discrimination analysis using the ABI
™
 TaqMan
®
 MTHFR 677 C>T assay 
(normalized fluorescence vs number of cycles).  
 
 
 
 
 
In addition to allelic discrimination analysis, scatterplot analysis was applied in this study. 
Scatterplot analysis is performed using two channels simultaneously. The genotype determination is 
based on regions found on the scatterplot, as well as relative expression of amplification across two 
channels. The plot accounts for different fold increase in each channel, and log transformed to 
highlight the differences in expression between samples.  
 
The scatterplot analysis for the MTHFR 677 C>T assay is presented in figure 3.3.2 with the legend 
and genotypes illustrated by table 3.3.1. Genotype determinations are made according to the FAM
™
 
/ VIC
®
 fluorescence, as indicated in the aforementioned table. The genotype distribution observed 
in the patient screening was: 62,5% wild type (CC), 16,67% heterozygous (CT) and 20,83% 
homozygous/mutant (TT). The control group consisted of two (33%) wild type (CC), two (33%) 
homozygous/mutant (TT) and two (33%) heterozygous (CT) samples.  
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Table 3.3.1. Legend for figure 3.3.1 and 3.3.2, 
indicating genotypes of the samples based on Allelic 
Discrimination data and Scatterplot analysis. 
Figure 3.3.2. Genotypes grouped by scatterplot analysis (FAM
™ 
 
fluorescence vs VIC
®
 fluorescence) of the ABI
™ 
 TaqMan
®
 MTHFR 
677 C>T assay. The legend is presented in table 3.3.1. 
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The allelic discrimination analysis for the MTHFR 1298 A>C assay is presented in figure 3.3.3 
with the legend and genotypes illustrated by table 3.3.2. The lines with intermittent circles represent 
the homozygous (C) allele, which is detected by VIC
®
-labelled probes, and lines without 
intermittent circles correspond to the wild type (A) allele detected by FAM
™
-labelled probes. 
Amplification of both alleles indicated through significant (i.e. above the threshold level) 
fluorescence of both dyes represents the heterozygous (AC) state. The threshold level is set at 
0.29558.  
 
Figure 3.3.3. Allelic Discrimination analysis using the ABI TaqMan® MTHFR 1298 A>C assay 
(normalized fluorescence vs number of cycles).  
 
 
 
 
The scatterplot analysis for the MTHFR 1298 A>C assay is presented in figure 3.3.2 with the 
legend and genotypes illustrated by table 3.3.4. The genotype distribution observed was: 50% wild 
type (AA), 37,5% heterozygous (CT) and 12,5% homozygous/mutant (TT). The control group 
consisted of two wild type (CC), two homozygous/mutant (TT) and two heterozygous (CT) 
samples.  
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Figure 3.3.4. Genotypes grouped by scatter analysis (FAM™ 
fluorescence vs VIC
®
 fluorescence) of the ABI TaqMan® MTHFR 
1298 A>C assay. The legend is presented in table 3.3.2. 
Table 3.3.2. Legend for figure 3.3.3 and 3.3.4, 
indicating genotypes of the samples based on Allelic 
Discrimination data and ScatterPlot analysis. 
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The allelic discrimination analysis for the HFE 845 G>A assay is presented in figure 3.3.5 with the 
legend and genotypes illustrated by table 3.3.3. Lines with intermittent circles represent the wild 
type (G) allele, which is detected by VIC

-labelled probes, while the lines without the intermittent 
circles signify the homozygous (A) allele detected by FAM
™
-labelled probes. Amplification of both 
alleles indicated through significant (i.e. above the threshold level) fluorescence of both dyes 
represents the heterozygous (GA) state. The threshold level is set at 0.1.  
 
 
Figure 3.3.5. Allelic Discrimination analysis using the ABI
™ 
TaqMan
®
 HFE 845 G>A assay 
(normalized fluorescence vs number of cycles).  
 
 
The scatterplot analysis for the HFE 845 G>A assay is presented in figure 3.3.6 with the legend and 
genotypes illustrated by table 3.3.3. The genotype distribution observed was: 70.83% wild type 
(GG), 25% heterozygous (GA), 0% homozygous/mutant (AA) and 4.17% undetermined. The 
potential causes for the failed reaction are numerous and include defects in the sample tube, 
pipetting error during reagent addition, erroneous tube position on the rotor of the instrument, 
ambient fluorescence of nearby sample tubes on the rotor may have interfered with the optical 
detector unit or the sample DNA may be degraded in the HFE region of interest thus preventing 
primer/probe binding and amplification/fluorescence. The control group consisted of five wild type 
(CC) and one heterozygous (CT) sample.  
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Figure 3.3.6. Genotypes grouped by scatter analysis (FAM™ 
fluorescence vs VIC
®
 fluorescence) of the ABI TaqMan® HFE 845 
G>A assay. The legend is presented in table 3.3.3. 
Table 3.3.3. Legend for figure 3.3.5 and 3.3.6, 
indicating genotypes of the samples based on Allelic 
Discrimination data and ScatterPlot analysis. 
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3.4.  Roche LightCycler
®
 480 II  
 
Custom designed Roche primers and HybProbe probes were used for the mutation detection 
experiments using melt curve genotyping with the Roche LC 480 II system. The investigation of 
MTHFR 1298 A>C in two sample batches at an annealing temperature of 52ºC yielded the 
amplification graphs presented in figures 3.4.1 (sample batch one) and 3.4.3 (sample batch two). 
These graphs illustrate successful amplification and fluorescence by the primers and HybProbe 
probes, respectively. The melting peaks depicted in figures 3.4.2 (sample batch one) and 3.4.4 
(sample batch two) clearly indicate the different genotype groups with wild types represented by 
blue peaks, heterozygotes in red and homozygotes in pink. Baseline colours (cyan, green, brown, 
etc.) represent NTCs, failed reactions or empty wells on the plate. Genotypes obtained were verified 
by the internal controls loaded on each plate, matching the DNA sequencing data.  
 
Application of an adapted version of the above protocol for mutation detection of MTHFR 677 C>T 
and HFE 845 G>A were unsuccessful. Optimization of the protocols for these SNPs included 
adjustments of the thermal cycling condition (specifically annealing temperature and melting curve 
parameters), MgCl2 titration, HybProbe probe titration and testing of the primer efficacy (through 
conventional PCR). The above approach for the optimization of the protocol was unsuccessful in 
yielding the desired results (data not shown).  
 
The difficulties encountered during this process resulted from the customized nature of the primers 
and HybProbe probes, as they were not standardized pre-designed assays, and constraints on 
available time for optimization and standardization of the LC 480 II system.  
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Figure 3.4.1. Amplification achieved in sample batch one using the Roche primers and HybProbe probes for MTHFR 1298 A>C 
(fluorescence at 498-640 nm vs time). The exponential phase was reached at ~00:43:33 and at ~1:05:00 the melting curve phase commenced.  
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Figure 3.4.2. Melting peaks achieved in sample batch one using the Roche primers and HybProbe probes for MTHFR 1298 A>C (fluorescence 
at 498-640 nm vs temperature). Blue peaks represent wild type, red peaks represent heterozygotes and pink peaks represent homozygotes. 
Baseline colours represent NTCs, failed reactions or empty wells on the plate.  
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Figure 3.4.3. Amplification achieved in sample batch two using the Roche primers and HybProbe probes for MTHFR 1298 A>C 
(fluorescence at 498-640 nm vs time). The exponential phase was reached at ~00:43:41 and at ~1:05:00 the melting curve phase commenced.  
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Figure 3.4.4. Melting peaks achieved in sample batch two using the Roche primers and HybProbe probes for MTHFR 1298 A>C (fluorescence at 
498-640 nm vs temperature). Blue peaks represent wild type, red peaks represent heterozygotes and pink peaks represent homozygotes. Baseline 
colours represent NTCs, failed reactions or empty wells on the plate. 
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The genotype distribution observed for MTHFR 1298 A>C achieved through application of the 
Roche LC 480 II system is presented in figure 3.4.5 and represents the combined frequencies for 
both sample batches. The total study population, which includes MS samples and controls, was 
found to consist of 40.29% wild type, 39.57% heterozygotes, 4.32% homozygotes and 15.83% were 
undetermined. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4.5. Genotype distribution of 139 samples obtained using the 
Roche LightCycler
®
 480 II system for MTHFR 1298 A>C. 90 MS 
patient samples (in blue) presented with 38 (42%) wild type, 30 (33%) 
heterozygotes, 4 (4%) homozygotes and 18 (20%) undetermined 
genotypes. 18 (37%) wild type were observed among the 49 control 
samples, 24 (51%) heterozygotes, 2 (4%) homozygotes and 4 (8%) 
were undetermined.  
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3.5.  Genotype-Phenotype Correlation in MS patients  
The genotype distribution for the two MTHFR gene mutations (Scholtz et al. 2002) and the HFE 
gene mutation (de Villiers et al. 1999) were similar to that previously described in the Caucasian 
population of South Africa. Further comparisons of allele frequency and genotype distribution were 
also not made between MS patient and control samples due to the small sample size of the control 
group.  
 
Following the standardisation of MTHFR and HFE mutation detection using the different RT-PCR 
methods described above, mutation status was correlated with biochemical parameters. Categorical 
variables were applied for comparison of the three genotypes (wild type, heterozygous and 
homozygous) for each SNP (MTHFR 1298 A>C, MTHFR 677 C>T and HFE 845 G>A) to specific 
biochemical parameters. Only 43 female MS patients (with a complete data set) were subjected to 
genotype-phenotype correlation which included serum iron parameters, as these values are naturally 
higher in males than females (MS is also more common in females than males). The male MS 
patients and controls were excluded from this analysis as the numbers were too small to perform 
meaningful statistical comparisons.  
 
Serum iron was found to be significantly different (P = 0.02) between the wild type and 
heterozygous MS patients with mutation 1298 A>C in the MTHFR gene. Figure 3.5.1 shows the 
low serum iron levels in heterozygotes and homozygotes relative to the wild type. The transferrin 
saturation presented with a similar pattern (data not shown) although the difference was not 
statistically significant (P = 0.10). CRP levels were found to be marginally higher (P = 0.07) in 
MTHFR 1298 A>C heterozygotes relative to the wild type, which is in accordance with increased 
inflammation in MS patients. No statistically significant differences were found in iron parameters 
or CRP levels in relation to the MTHFR 677 C>T  and HFE 854 G>A mutations.  
 
 
 
 
 
 
 
 
Chapter Three: Results 
 
65 
 
Table 3.5.1. Comparison of iron parameters among MTHFR 1298 A>C genotypes in a female 
study population.  
 
CRP = C-reactive protein, He = Heterozygote, HGB = haemoglobin, Ho = Homozygote, S-Iron = 
serum iron, STD = standard deviation, Tf = transferrin. * Reference Ranges: S-Iron(µmol/l)=10.0-
30.0; Tf (g/l)=2.0-3.6; % Tf Saturation=20-50; Ferritin (µg/l)=10-291; HGB (g/dl)=13.0-17.0; CRP 
(mg/l)=0.0-10.0. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5.1. Comparison of serum iron concentrations (S-Iron) among 
MTHFR 1298 A>C genotypes in a female study population. Mean ± 
STD: Wildtype
a
: 18.64 ± 7.15; He
b
: 12.37 ± 5.91; Ho
c
: 13.72 ± 5.15; 
Significant difference: P–value: 0.02 ab 
 
 
 
MTHFR 1298 A>C 
  
Wildtype
a
 He
b
 Ho
c
 
P-value 
(n=18) (n=20) (n=5) 
Mean ± STD Mean ± STD Mean ± STD 
ab
 
ac
 
bc
 
S-Iron (µmol/l)* 18.64 ± 7.15 12.37 ± 5.91 13.72 ± 5.15 0.02 0.42 1.00 
Tf (g/l)* 2.66 ± 0.40 2.58 ± 0.49 2.47 ± 0.54 1.00 1.00 1.00 
% Tf Saturation* 28.53 ± 10.27 20.27 ± 11.47 20.31 ± 6.10 0.10 0.53 1.00 
Ferritin (µg/l)* 86.17 ± 68.18 79.08 ± 97.43 62.64 ± 70.97 1.00 1.00 1.00 
HGB (g/dl)* 13.61 ± 2.81 13.26 ± 1.13 12.93 ± 1.25 1.00 1.00 1.00 
CRP (mg/l)* 2.93 ± 2.31 6.65 ± 4.96 3.90 ± 3.35 0.07 1.00 0.68 
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The aetiology of multiple sclerosis (MS) remains largely unknown, due to its multifactorial nature 
with poor nutrition and genetic factors contributing to the risk. Several investigations highlighted 
the important role of the genetic component influencing disease susceptibility and progression (Bell 
et al. 1996, Ebers et al. 1996). In the present study genetic variations that influence iron and folate 
metabolism was studied in the context of MS, aimed at the development of a method to apply a 
pathology supported genetic test. This requires that the genetic profile is correlated with the 
patient‟s biochemistry (including serum iron parameters) to assess gene expression and response to 
treatment and/or lifestyle changes.  
 
The objective of this study was not to prove or disprove the clinical utility of nutrigenetic testing in 
MS patients, but rather to contribute the laboratory component of performing MTHFR and HFE 
gene mutation detection accurately in the Pathology Research Facility of the University of 
Stellenbosch using high-throughput RT-PCR analysis. The same DNA samples were therefore 
analysed using three different RT-PCR methodologies for comparison with direct DNA sequencing 
as the gold standard. For the first time, high-throughput assays for clinically useful mutations in the 
MTHFR and HFE genes can now be offered as a routine service at the Tygerberg Academic 
Hospital. 
 
In the first part of the current study, comparison of three mutation detection systems, namely: 
Corbett Rotor-Gene
™
 6000 5-plex HRM, ABI
™
 7900HT and the Roche LightCycler
®
 480 II system 
was carried out. Control samples of known genotype using direct DNA sequencing as the gold 
standard were included in each run to prove analytical validity of the mutation detection methods 
used. The three instruments were compared on the basis of accuracy, sensitivity, cost-effectiveness 
and ease of operation. Three SNPs were investigated, two in the MTHFR and one in HFE gene, 
through the application of the ABI TaqMan
® 
Genotyping Assays. In the second part of the study, 
statistical analysis was employed to correlate different genotypes with specific biochemical 
measurements performed in a subset of the study population. In these 43 MS (all female) patients 
included for genotype-phenotype analysis standard methodology was used for biochemical 
determinations as previously described (van Rensburg et al. 2006). These results were discussed in 
the context of a newly developed pathology supported genetic testing approach used as part of a 
health outcomes research project aimed at improved quality of life in MS patients.  
 
Methodology comparison 
Applied Biosystems
®
 TaqMan
®
 SNP Genotyping (7900HT) 
The ABI
™
 7900HT Fast Real-Time PCR System was used with pre-designed and optimized ABI
™
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TaqMan
®
 SNP Genotyping assays in this study. The 7900HT can run 96 or 384 reactions 
simultaneously. The assays are multiplexed, designed for end-point analysis (which employs 
fluorophore-labelled probes) and have been standardized to work with TaqMan
®
 Universal PCR 
Master Mix under one thermal cycling condition (table 2.3).  
 
The assays consist of unlabelled sequence-specific forward and reverse primers for amplification of 
a polymorphic target sequence. Additionally, the assay contains two TaqMan
® 
MGB probes with a 
reporter dye at the 5‟ end referred to as VIC dye connected to the 5‟ end of allele 1 probe and 
FAM
™
 dye linked to the 5‟ end of the allele 2 probe. At the 3‟ end of each probe, a minor groove 
binder (MGB) is attached. This allows for increase in the melting temperature (Tm) of a given 
probe length (Afonina et al. 1997; Kutyavin et al. 1997). This modification allows for designing 
shorter probes with greater differences in Tm values between matched and mismatched probes 
resulting in precise allelic discrimination. The probe hybridization efficiency may be reduced with a 
single nucleotide mismatch between the probe and target sequence which results in reduction of 
reporter dye cleaved from a quenched probe. Moreover, the AmpliTaq Gold DNA polymerase 
found in the TaqMan
®
 Universal PCR Master Mix dislocates the mismatched probe without 
cleaving it. All the above-mentioned factors minimize the production of the non-specific 
fluorescence signal and thus increase the accuracy of results.  
 
ABI
™
 TaqMan
®
 SNP Genotyping assays employ amplification of the target sequence through PCR 
and thereafter post-PCR read and analysis can be applied using allelic discrimination. During target 
amplification, the TaqMan
® 
MGB probe annealing takes place between the forward and reverse 
primer sites on the complementary sequence. Upon annealing, the proximity of the reporter dye to 
the quencher dye coincide in quenching of the reporter fluorescence through Forster-type energy 
transfer (Fluorescence resonance energy transfer (FRET); Förster, 1948; Lakowicz, 1983). 
Extension of the primers bound to the target sequence takes place through AmpliTaq Gold DNA 
polymerase. This polymerase carries out cleavage of the probes hybridized to the target sequence, 
which results in the separation of reporter dye from the quencher dye and therefore increase in 
fluorescence by the reporter. The fluorescence signal corresponds to the presence of the specific 
allele in every sample. Fluorescence by both dyes signifies the presence of both alleles and thus 
heterozygosity of the sample.  
 
In MTHFR 677 C>T genotyping, the ABI
™
 TaqMan
® 
probes were designed on the reverse strand –
hence the detection was reported as a change from a G>A. The VIC
®
-labelled probes only bound to 
alleles containing guanine (G) in the 677-nucleotide position of MTHFR, corresponding to the wild 
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type allele and therefore detection in the yellow channel. FAM
™
-labelled probes were assigned to 
the alleles containing adenine (A) in nucleotide position 677 of the MTHFR gene, corresponding to 
the presence of the SNP and therefore detection in the green channel. For the purposes of this study, 
all RT-PCR results for MTHFR 677 C>T were presented in the forward notation to comply with 
international standards. Therefore wild types are designated CC, heterozygotes CT and 
homozygotes TT.  
 
The
 
MTHFR 1298 A>C assay probes were also designed on the reverse strand, resulting in 
detection of a T>G nucleotide change. The VIC

-labelled probes were designed to bind to alleles 
containing guanine (G) in the 1298-nucleotide position of MTHFR gene, corresponding to the 
mutant/ homozygous allele, and therefore detection in the yellow channel. FAM
™
-labelled probes 
were appointed to the alleles containing thymine (T) in nucleotide position 1298 of MTHFR, 
representing wild type alleles and therefore detection in the green channel. As with the MTHFR 677 
C>T SNP, all RT-PCR results for MTHFR 1298 are presented in the forward notation to comply 
with international standards. Therefore wild types are designated AA, heterozygotes AC and 
homozygotes CC.  
 
The HFE G845A (C282Y) ABI
™
 TaqMan
®
 assay consisted of two fluorophore-labelled probes: one 
for each allele. The VIC

-labelled probes were designed to specifically bind to the allele that 
contains guanine (G) in nucleotide position 845 of the gene, analogous to the wild type allele. The 
FAM
™
-labelled probes in this assay bound only to the allele containing adenine (A) in position 845, 
representing the presence of the C282Y mutation.  
 
Corbett Rotor-Gene
™
 6000 / QIAGEN Rotor-Gene Q 
The Corbett Research Rotor-Gene
™
 6000 Series is a Real-Time PCR instrument used for target 
amplification, endpoint genotyping, as well as High Resolution Melt (HRM) analysis. This system 
can run up to 36 or 72 reactions simultaneously, depending on the rotor type employed. The 
software provides simplicity as well as a superior open experimental platform for advanced users. 
The Rotor-Gene
™
 6000 instrument can be applied in multiplex reactions with six different 
excitation sources (e.g. Blue, Green, Yellow, High Resolution Melt) and six detection filters 
combined with a fixed optical path. This allows for reduced calibration and compensation as well as 
minimizing the fluorescence variability between each sample. An electric current is conducted in 
one direction by a light emitting diode, which excites the samples from the bottom of the chamber. 
This allows for energy transmission at the base of clear, thin walled PCR tubes. A photomultiplier 
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then collects the fluorescence emitted from the samples. The fixed optical path ensures constant 
excitation for every sample as the rotation around the chamber takes place.  
 
The Corbett Research Rotor-Gene
™
 6000 Series Multiplexing System provides several analysis 
modes such as Quantitation analysis, two standard curve analysis, Delta Delta Ct Relative 
Quantitation, Melt Curve analysis, Comparative Quantitation, Allelic Discrimination, Scatter-Plot 
Analysis, Endpoint Analysis as well as High Resolution Melt analysis. In this study, ABI
™
 
TaqMan
®
 SNP Genotyping assays were also employed with the Rotor-Gene
™
 6000 instrument.  
 
Roche LightCycler

 480 II  
The Roche LightCycler
®
 480 II system enables real-time performance of PCR with rapid cycling of 
either 96 or 384 samples. The instrument allows for several applications such as Relative 
Quantification, Endpoint Genotyping and Melt Curve Genotyping. The optical detection system can 
detect a broad range of sequence-dependent (e.g. HybProbe probes and hydrolysis probes) as well 
as sequence-independent probes (e.g SYBR Green 1). The detection unit consists of two parts. The 
lamp unit uses a Xenon reflector lamp as excitation light source with a wavelength ranging from 
430 to 630nm, allowing a variety of different fluorophores to be used. The other is the optic unit 
consisting of several parts such as liquid light guide with light pipe, the emission filters wheel, the 
excitation filters wheel and the CCD camera with camera optics. The liquid light guide allows for 
the light emitted by the Xenon lamp to be passed to the optic unit, where the light pipe converts the 
round to rectangular profile shaping that of the PCR multiwall plate.  The revolving filter wheel 
driven by a stepper motor positions six different filters, according to which the wavelength of the 
amplification reaction by the excitation fluorophores is determined. The light passed through the 
excitation filter is then projected on the PCR multiwall plate through a large field lens collecting the 
rays from the plate. The fluorescent light emitted by the excited fluorophores during the 
amplification reaction is passed on into the optics module in a vertical position. This limits the 
shading effects within the plate wells, as well as limiting distortion or variation in the signals being 
captured from the wells placed on the edges of the plate compared to the centered wells allowing 
homogeneous sensitivity of the complete plate. The CCD camera then detects the fluorescence 
signals. Parallel to this, a reference channel is used to measure the intensity of the Xenon lamp in 
order to compensate for possible intensity fluctuation that may affect the fluorescence signals, 
ensuring low intra- and inter-assay variation.  
 
In the present research study Melt Curve Genotyping was applied using HybProbe probes suitable 
for SNP detection. During this detection format two custom designed sequence-specific 
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oligonucleotide probes were labeled with two different fluorophores, donor dye or fluorescein and 
an acceptor dye, LightCycler
®
 Red 640. The probes hybridize to the polymorphic target sequence of 
the amplified DNA sequence from the 5‟ to the 3‟ orientation, resulting in close proximity of the 
dyes. Fluorescein found at the 3‟ end of the HybProbe is excited at a wavelength of 480nm, which 
results in energy discharge and therefore excitation of the acceptor dye/ LightCycler
®
 Red 640 
bound to the 5‟ end of the second HybProbe probe emitting light at a longer wavelength, resulting 
in signal detection. For the HybProbe probe SNP detection uses Melt Curve analysis. In this 
detection format, binding of the HybProbe probe to the complementary template takes place at a 
temperature below that of the Tm of the oligonucleotide probe resulting in the close proximity of 
the dyes and production of fluorescence resonance energy transfer (FRET). As the temperature 
rises, the probes melt off at their analogous Tms and therefore inhibiting FRET production. This 
results in a decreased fluorescence signal. The temperature at which the sensor probe melts is 
dependent on the polymorphic target sequence. In the presence of the SNP in the target region with 
the hybridized sensor probe, the complex becomes destabilized and melts at a lower temperature in 
comparison to the wild type target region. 
 
Comparison 
The three above-mentioned RT-PCR mutation detection systems, Corbett Rotor-Gene
TM
 6000 5-
plex HRM, ABI
TM
 7900HT and LightCycler
®
 480 II, are comparable in terms of accuracy, 
sensitivity and specificity since the exact same genotypes were observed for the individual samples 
analysed. However, it must be emphasised that it was a time consuming process to standardise the 
MTHFR and HFE gene assays on each individual instrument, with only the MTHFR A1298C assay 
analytically validated finally on all three instruments. Failure to successfully perform the MTHFR 
677C>T and HFE 845G>A assays using the Roche LightCycler
®
 480 II (only available in the 
laboratory from June 2010) demonstrates the difficulty of providing consistent results due to the 
many variables that needs to be taken into account to obtain a reliable result. While standardised 
pre-designed assays were used on the Corbett Rotor-Gene
TM
 6000 5-plex HRM and ABI
TM
 7900HT 
instruments, genotyping on the Roche LightCycler
®
 480 II was performed with custom designed 
primers and probes. Although standardised assays are also available for melt-curve genotyping 
using the Roche LightCycler
®
 480 II, the cost in relation to the number of reactions that can be 
performed was restrictive. 
 
In terms of cost effectiveness, ease of operation and optimization, the Corbett Rotor-Gene
TM
 6000 
5-plex HRM thermal cycler, with use of the ABI
TM 
TaqMan Genotyping assays was found to be the 
most efficient for mutation detection using relatively small sample batches (maximum of 36 or 72, 
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depending on the rotor type). For larger sample batches, e.g. 96 or 384, ABI
TM 
TaqMan
®
 SNP 
Genotyping assays with either the Roche LightCycler
®
 480 II or ABI
TM 
7900 HT is most 
convenient. 
 
Genotype-Phenotype Correlation 
The objective of this study was not to prove or disprove the clinical utility of nutrigenetic testing in 
MS patients, but rather to contribute the laboratory component for MTHFR and HFE gene mutation 
detection as part of an integrated pathology supported genetic testing approach. The limited 
genotype-phenotype correlation study preformed in a subset of 43 MS patients was in agreement 
with this concept.  
 
In this study, a novel finding was that heterozygotes and homozygotes for MTHFR 1298 A>C, 
presented with lower serum iron in comparison to subjects without the C-allele (P = 0.02). This 
association supports a German case-control study conducted by Klotz et al. (2009), where MTHFR 
1298 A>C was found to influence neurodegeneration and the incidence rate of MS. Furthermore, 
CRP levels were found to be marginally significantly higher (P = 0.07) in the MTHFR 1298 A>C 
mutation-positive subjects, possibly linking inflammation to the presence of the MTHFR 1298 A>C 
mutation. This supports the findings of Soilu-Hänninen et al. (2005) that reported that CRP values 
were similar in patients with MS and in healthy controls but higher during MS relapses than in 
remission (P = 0.01). 
 
In comparison, the MTHFR 677 C>T mutation showed no correlation with transferrin saturation, 
ferritin, haemoglobin or CRP levels. Mutation 677 C>T is known to reduce MTHFR enzymatic 
activity in cultured fibroblasts and in peripheral lymphocytes (Klotz et al. 2010). However 
Linnebank et al. (2004) and Wullner et al. (2005) have previously reported that MTHFR 1298 
A>C, influences neurodegeneration irrespective of the MTHFR 677 C>T variant. The results of the 
present study imply that this may be related to decreased iron concentrations, although the exact 
biochemical mechanism is not known.  
 
The importance of studying biochemical parameters related to iron and folate metabolism in MS 
patients is supported by the fact that iron deficiency is linked to folate deficiency (Thoradeniya et 
al. 2006). Homocysteine is a marker of vitamin B deficiencies and inflammation. The connection 
between inflammation, iron and folate is considered to be of particular relevance in MS patients 
(Connor and Menzies, 1996; Kotze et al. 2001; van Rensburg et al. 2006; van Rensburg et al. 2009, 
van Rensburg and van Toorn, 2010). Higher homocysteine levels frequently reported in MS patients 
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imply impaired methylation. Low levels of vitamin B12 are associated with low iron uptake and 
atrophy of glands producing intrinsic factor in the stomach. Inhibition of vitamin B12 uptake leads 
to the development of pernicious anaemia and subacute degeneration of the spinal cord, a condition 
that may mimic MS (Coyle, 2006; Herndon, 2006; Surtees, 1993).  
 
Optimal functioning of the folate-vitamin B12-methyl transfer pathway is a prerequisite for myelin 
production and maintenance (Selzer et al. 2003). It has been shown that while functional 
polymorphsisms in genes of the methyl transfer pathway may cause inadequate myelination and 
serious disability from childhood, supplementation with the chemical substrate following each 
metabolic block could restore the myelin as well as some of the functional deficiencies (Surtees et 
al. 1991). Demyelination may occur when the substrates or co-factors of the folate pathway 
(including B vitamins and zinc) are depleted (Selzer et al. 2003). The latter study furthermore 
showed that demyelination may also follow when this metabolic pathway is blocked by nitrous 
oxide anaesthesia, since nitrous oxide causes irreversible oxidation of the cobalt in vitamin B12.  
 
Genetic variation in the MTHFR gene indicates an increased requirement of folate and other B-
vitamins to prevent homocysteine accumulation, destruction and damage of the DNA integrity, 
dysregulation of gene expression, chromatin destruction and thus epigenetic dysregulation. In 
addition, folate is necessary for red blood cell formation and growth. Due to the water-soluble 
nature of this B-vitamin, folate is not stored in the body in large amounts, thus its continual supply 
through diet is essential to maintain its normal levels in the serum. Decreased levels of folate may 
lead to folate-deficiency anaemia presented as enlarged red blood cells known as megalocytes or 
megaloblasts (megaloblastic anemia) in the bone marrow.  Homozygotes with the two copies of the 
677 C>T mutations have only 30% of normal MTHFR enzyme activity. Compound heterozygotes 
with both the 677 C>T and 1298 A>C mutations have less than 50% of normal MTHFR enzyme 
activity. MTHR enzyme activity could be restored to normal with folate supplementation 
(nutrigenetics application). Caution should also be taken with administration of certain drugs that 
interfere with folate metabolism, especially in patients with deleterious mutations in the MTHFR 
gene that may be switched on in the presence of low folate status (pharmacogenetics application).  
 
Variation in the HFE variant G>A, is usually associated with over-absorption of iron from the diet 
(nutrigenetics application) and may result in haemochromatosis. The risk of organ damage is 
significantly increased in homozygotes with high serum ferritin and transferrin saturation levels. 
However, the risk of organ damage is usually not increased in heterozygotes. In a study to 
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determine the effects of these genetic mutations in MS, Kotze et al. (2006) reported no organ 
damage in MS patients heterozygous or homozygous for mutation C282Y in the HFE gene.  
 
The importance of iron deficiency in the aetiology of MS was emphasized by the finding that 
oligodendrocytes need iron to synthesize myelin (Connor and Menzies, 1996). A case study 
including two children with relapsing-remitting MS reported significantly lower iron concentrations 
in both subjects (van Toorn et al. 2010). Iron supplementation resulted in sustained remission and 
no further relapses in these children. The relevance of iron deficiency in MS may have been missed 
previously because iron is traditionally associated with oxidative damage, and iron chelation would 
rather be considered appropriate to prevent oxidation during demyelination (van Rensburg et al. 
2009). The presence of iron is however stringently controlled under normal circumstances as 
intracellular iron is either bound up inside proteins such as the haem groups of cytochromes and 
catalase or sequestered by the iron transporters (transferrin and ferritin). Within the 
oligodendrocytes a highly functional antioxidant system is continually present to scavenge free 
radicals (Baud et al. 2004).  
 
Pathology supported genetic testing 
In April 2009, the Department of Pathology at Stellenbosch University initiated a process to 
develop pathology supported molecular genetic tests, which is based on an integrated service- and 
research approach (Schneider 2009). The aim is to match disease diagnosis and therapeutic design 
with the clinical picture, pathology, environmental risk factors and genetic profile of the patient. 
This new test concept requires that (1) genetic testing is performed within a specific clinical and 
pathology/biochemical profile, (2) the patient report contains both the biochemical and genetic test 
results for clinical application in the context of relevant documented environmental factors, and (3) 
gene expression and monitoring of response to treatment are assessed through the accompanying 
pathology and genetic test parameters (Kotze et al. 2009).   
The limitations of DNA testing – where a positive test does not necessarily mean that the associated 
disease will develop and a negative test does not exclude other risk factors not included in the test – 
can be overcome with the application of pathology supported genetic testing. Furthermore, to 
ensure clinical usefulness of genetic variations evaluated as part of this process, careful review of 
the literature is necessary to prevent the use of SNPs of uncertain functional significance in genetic 
tests. In contrast, genome wide association studies may identify risk alleles in the absence of 
supporting data on relevant metabolic impairments. This process therefore involves the use of the 
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Gknowmix Software applied in conjunction with high-throughput real-time polymerase chain 
reaction (PCR) technologies that are benchmarked against direct DNA sequencing as the gold 
standard (Kotze et al. 2009). In order to address the important ethical and scientific issues 
pertaining to pathology supported gene-based intervention, the information must preferably be 
captured in a database preferably as part of properly designed and ethically approved research 
project that will advance evidence-based medicine (Kotze et al. 2009).  
Combined service and research approach 
The present investigation represents a sub-study of the project entitled “The development and 
commercialization of a comprehensive gene-based, pathology supported intervention program for 
improved quality of life in patients diagnosed with multiple sclerosis (MS)”. This translational 
research project includes both a service and a research component, registered under number 
N07/09/203. Integration of data relating to the spectrum of risk factors influencing iron and folate 
metabolism provides a major healthcare opportunity to improve the quality of life for patients with 
demyelinating diseases such as MS (van Rensburg and van Toorn, 2010). 
Autoimmunity is considered the major cause of chronic, inflammatory diseases such as MS. 
However, about one third of patients do not respond to immune modulatory therapy (Axtell et al. 
2010; Byun et al. 2008). Failure to identify a major genetic component underlines the importance of 
a step-wise risk evaluation process that aims to support myelin production in patients at an early 
stage of demyelination, while stabilising the disease progression in more severely affected patients 
through a personalized treatment programme. The novel approach of the present study includes 
assessment of genetic susceptibilities and lifestyle risk factors in relation to the metabolic profile of 
each patient, as genetic differences may affect how drugs and nutrients are metabolised by the body, 
taking into account relevant gene-drug (pharmacogenetics) and gene-diet (nutrigenetics) 
interactions.  The unique program includes the following (Kotze et al. 2010):   
 Combines pathology,  pharmacogenetics and nutrigenetics in one test application; 
 Assesses biochemical levels and genes involved in iron dysregulation and methylation; 
 Nutrigenetics is applied to develop a supplementation program; 
 Pharmacogenetics is applied for contra-indication of anti-folate drugs (e.g. methotrexate); 
 Blood levels of iron parameters, homocysteine, CRP and cholesterol are measured; 
 Folate-Vit. B12, Vit. D and iron levels are monitored for optimal myelin production; 
 Individualised reports are generated with an integrative software program. 
 Offers an integrated, personalized treatment regimen for each patient; 
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 Inexpensive approach compared to conventional treatments. 
 
The assessment of biochemical levels and genes involved in iron dysregulation and the methylation 
process forms the core element of this new healthcare approach applied for the first time in MS 
patients.  Clinical management is improved through the concurrent application of diagnostic 
pathology tests in conjunction with predictive nutrigenetics and pharmacogenetics. The following 
steps are involved: 
1. Documentation of the patient’s medical history and environmental risk:   
 Medical status, including neurological examination, infections and family history, 
 Nutrition status, including nutrient intake, food allergies or intolerances, 
 Existing medication use and side-effects, 
 Lifestyle evaluation for risk factors, including smoking, body mass index (BMI).  
2. Laboratory testing to tailor the treatment strategy: 
 Pathology tests for relevant biochemical and haematological determinations, 
 Genetic testing according to family history/iron status/homocysteine levels, 
 Immunological testing to avoid histamine production. 
3. Interpretation of test results provided in an integrated report, including:   
 Disease status, 
 Environmental and lifestyle risk factors, 
 Treatment guidelines for implementation. 
4. Intervention according to combination of genetic and environmental factors: 
 Target gene-environmental mismatches: genetic variations or mutations determine different 
responses to medication or environmental exposure, 
 Pharmacological or nutritional information is combined with the DNA and clinical profile 
for treatment aimed at the regeneration of myelin and avoidance of risk factors. 
5.  Monitor treatment response and compliance management: 
 Impact on disease status is monitored after implementation of a nutrigenetics diet support 
program and a Mediterranean style diet, including no smoking, supplements of iron if 
indicated, folate, Vit. B12, antioxidants, lecithin, Vit. D, mineral, essential fatty acids and 
amino acids required for myelin production and maintenance in oligodendrocytes (van 
Rensburg et al. 2006). 
The therapeutic strategy combines gene testing, pharmacogenetics and nutrigenetics in one 
treatment where a healthy diet and supplement programme are used in addition to medication where 
appropriate. Particularly, in the approximate one-third of patients who are non-responders to 
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Interferon beta therapy, this approach may assist to improve the quality of life in patients who do 
not respond to drugs due to the fact that they may belong to a sub-group of MS patients with a 
metabolic form of demyelination.  
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In this study, the three mutation detection systems (Corbett Rotor-Gene
TM
 6000 5-plex HRM, 
ABI
TM
 7900HT and Roche LightCycler
®
 480 II) investigated were found to be comparable in terms 
of accuracy, sensitivity and specificity. In terms of cost effectiveness, ease of operation and 
optimization, the Corbett Rotor-Gene
TM
 6000 5-plex HRM thermal cycler, with use of the ABI
TM 
TaqMan Genotyping assays was found to be the most efficient for mutation detection using 
relatively small sample batches (maximum of 36 or 72, depending on the rotor type). For larger 
sample batches, e.g. 98 or 384, ABI
TM 
TaqMan
®
 SNP Genotyping assays with either the Roche 
LightCycler
®
 480 II or ABI
TM 
7900 HT is recommended.  
 
Although considerable research into the causes of MS has resulted in large volumes of information, 
much of this information is contradictory and not generally or routinely applicable. MS provides an 
excellent example of a complex disease that is best addressed by pathology supported genetic 
testing approach. What this means, is that genetic testing is performed within a specific 
pathology/biochemical and clinical profile, that both the biochemical and genetic test results are 
provided in a patient report together, and that gene expression and/or response to treatment is 
monitored through these accompanying pathology and genetic test parameters. A specific and 
focused approach to the screening of MS is now applicable for the first time at the Pathology 
Research Facility of the University of Stellenbosch. This application aims to facilitate the support of 
myelin production in patients at an early stage, as well as stabilizing disease progression of 
demyelinating diseases in more developed patients, through a personalized nutrition support 
program. This approach is relatively less expensive when compared to more conventional treatment 
programs of MS, some of which may be contra-indicated due to genetic factors involved in drug 
response.  
 
Application of the above approach to facilitate improved clinical management of MS patients 
requires careful ethical consideration. This was addressed in the research protocol (N07/09/203), 
which forms the foundation of our combined service and research approach as follows: 
 The genetic test will only screen for specific genetic alterations expected to provide useful 
information in relation to treatment/diet intervention.  
 Detection of genetic alterations (positive test) implies that other family members may also 
have the genetic change(s). 
 Failure to detect a specific genetic alteration (negative test result) does not exclude 
undefined gene mutations or other risk factors not tested for. 
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 Early detection or pre-clinical diagnosis of treatable or preventable genetic diseases (e.g. 
hereditary haemochromatosis caused by mutations in the HFE gene) is beneficial. 
 Genetic testing may result in better motivation for lifestyle changes or targeted treatment, or 
possibly anxiety when genetic risk factors are identified in an individual without clinical 
symptoms of a disease. 
 The genetic material is stored for reference purposes or to perform follow-up testing and 
may be stored and included in a genetic database for research related to the test requested, 
unless declined by the pateints.  
 Identification of genetic alterations in individuals with a family history or clinical features of 
the associated disease will not impact further on insurance, while exclusion of a genetic 
defect in a family member could be beneficial for insurance purposes in some instances.  
 A positive genetic test does not mean that the person has a genetic disease or will develop 
the condition, but it can increase the risk of disease in the absence of appropriate risk 
reduction intervention. 
 
All personal and medical information of patients must be and are kept confidential and not made 
available to others without permission of the tested individual. In the case of genetic testing the 
information obtained may not only relate to the tested individual, but also his/her close family 
members. Therefore it is preferable that both pre- and post-test counseling be provided by registered 
genetic counsellors to all patients referred for genetic testing. However, it is now accepted 
internationally that because of the small number of registered genetic counsellors available and the 
diversity of the types of genetic tests, other knowledgeable healthcare professionals will need to 
help educate their patients about the genetic basis of monogenic and multi-factorial diseases, the 
clinical/biochemical consequences, and the genetic testing options available. Accurate, full and 
unbiased information should be provided to individuals and families to enable them to make 
informed decisions about genetic testing and treatment/intervention options.  
 
In conclusion, all the aims of the study have been accomplished. We demonstrated the optimization 
steps needed before genetic testing can be applied as part of a pathology supported gene-based 
intervention strategy using high-throughput RT PCR. These were included in the standard operating 
procedures (SOP‟s) developed for use in the Pathology Research Facility. The demonstration of 
reduced serum iron levels correlating with variation in the MTHFR gene in a subgroup of MS 
patients furthermore opened a new realm of research possibilities for future studies in the field of 
MS and other demyelinating diseases. 
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PARTICIPANT INFORMATION AND INFORMED CONSENT FORM FOR 
RESEARCH INVOLVING GENETIC STUDIES 
 
 
TITLE OF RESEARCH PROJECT: 
The development of a comprehensive gene-based, pathology supported intervention program for 
improved quality of life in patients diagnosed with multiple sclerosis (MS). 
 
REFERENCE NUMBER: N07/09/203 
 
PRINCIPAL INVESTIGATOR: Prof SJ van Rensburg 
 
ADDRESS: Division of Chemical Pathology,  Tygerberg Academic Hospital / University of 
Stellenbosch, Tygerberg  7505  
 
CONTACT NUMBER: (021) 938 4611 
 
We would like to invite you to participate in a research study that involves genetic analysis and 
possible long-term storage of blood or tissue specimens.  Please take some time to read the 
information presented here which will explain the details of this project.  Please ask the study staff 
or doctor any questions about any part of this project that you do not fully understand.  It is very 
important that you are fully satisfied that you clearly understand what this research entails and how 
you could be involved.  Also, your participation is entirely voluntary and you are free to decline to 
participate.  If you say no, this will not affect you negatively in any way whatsoever.  You are also 
free to withdraw from the study at any point, even if you do agree to take part initially.  
 
This research study has been approved by the ethics Committee for Human Research at 
Stellenbosch University and it will be conducted according to international and locally accepted 
ethical guidelines for research, namely the Declaration of Helsinki, and the SA Department of 
Health‟s 2004 Guidelines: Ethics in Health Research: Principles, Structures and Processes. 
 
What is Genetic research? 
Genetic material, also called DNA or RNA, is usually obtained from a small blood sample.  
Occasionally genetic material is obtained from other sources such as saliva or a cheek swab. Genes 
are found in every cell in the human body.  Our genes determine what we look like and sometimes 
what kind of diseases we may be susceptible to.  Worldwide, researchers in the field of genetics are 
continuously discovering new information that may be of great benefit to future generations and 
also that may benefit people today, who suffer from particular diseases or conditions. 
 
What does this particular research study involve? 
This study will search for hereditary factors that can influence the development of multiple sclerosis 
(MS) and also look for certain nutrition and lifestyle factors that may interact with genetic risk 
factors. The study will aim to provide further evidence that nutrition intervention can improve 
quality of life, at least in a subgroup of patients who have different requirements for certain 
nutrients (e.g. iron, folate) due to genetic alterations. Biochemical determinations of blood and urine 
will also be determined for correlation and to assess the influence of nutrition intervention on 
quality of life in MS patients. Individuals without MS will also be included in the study as controls, 
to compare the impact of genetic factors in relation to biochemical parameters and clinical outcome. 
You will be provided with a personalised lifestyle modification plan approved by a clinician based 
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on your medical and family history and the results of pathology and genetic tests. Although you 
may receive the lifestyle and diet recommendations for immediate implementation, details on any 
specific genetic alteration identified will not be provided without genetic counselling by a clinician 
or registered genetic counsellor. 
  
Why have you been invited to participate? 
You have been invited to participate as you have been diagnosed with MS, or as a control subject 
who may have expressed an interest in participating to draw comparisons. We would like to use the 
information obtained from you to determine whether certain risk factors occur more often in 
affected patients than individuals who do not have MS. We are also interested to find out how your 
genetic profile may influence your response to the intervention program that may be recommended.   
 
What procedures will be involved in this research? 
You will be asked to fill in forms with questions pertaining to your health status, family history, use 
of (chronic) medication, etc. and a number of lifestyle factors such as alcohol consumption, 
smoking etc. Your length and weight may be measured and five small blood bottles of 5 ml each 
(about four tablespoons) and/or a tissue biopsy (e.g. cheek swab) may be taken for laboratory 
determinations. You may also be requested to collect urine samples in containers that will be 
provided, for biochemical tests.  
 
Are there any risks involved in genetic research? 
You may experience minor pain or bruising at the site where specimen is taken for laboratory 
testing. In the event that genetic testing is performed in families, non-paternity may be revealed and 
it is therefore important that adoption be reported at the time that specimens are obtained for genetic 
testing. Based on your family history and personal health profile, genetic counselling/consultation 
may be advisable. Some insurance companies may mistakenly assume that taking part in genetic 
research indicates a higher risk for disease. Thus, no information about you or your family will be 
shared with such companies. Since the techniques to be used may be experimental and thus possibly 
unreliable, a quality control system will be implemented as part of this project whereby some of the 
specimens used for the study may be analysed by different laboratories, possibly using different 
mutation detection methods. 
 
Are there any benefits to your taking part in this study and will you get told your results? 
Your blood will be tested to develop an individualized nutrition intervention program based on the 
outcome of the laboratory results. The test results will be provided to a clinician who will explain 
this to you or refer you to a registered dietician who has been trained to interpret the genetic results 
in the context of relevant lifestyle risk factors and blood biochemistry that may reflect gene-
environment interaction. Some of the tests that will not have an immediate effect on the 
intervention strategy may be done at a later time when batches of samples are available; this will be 
done to limit testing time and costs involved. This research is expected to benefit people with the 
same condition in the future as they might be in a position to get treatment earlier to improve 
quality of life.  
 
Results of routine biochemical tests such as iron parameters and homocysteine levels will be made 
available to you but genetic results will only be made known to you if they indicate that you may: 
 
 Have a predisposition or a genetic risk factor that can be minimised by nutrition and 
lifestyle changes 
 Need genetic counselling  
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OR 
 If you request a report.  
 
It is important to understand that the individualised intervention program to be provided in your test 
report may or may not improve your quality of life, as it is experimental and clinical validity still 
needs to be evaluated in a double-blind, randomised clinical trial. 
 
How long will your blood be stored and where will it be stored? 
Your specimen will be stored at the University of Stellenbosch Medical School in a specifically 
dedicated fridge or freezer for at least 5 years or at the laboratory that performed the same test(s) as 
a routine service. A material transfer agreement will be signed by a representative of the university 
if/when your specimen is shipped from the University of Stellenbosch to another laboratory or 
country (e.g. for quality assurance, collaborative research). 
 
If your blood is to be stored is there a chance that it will be used for other research? 
 
Your specimen will only be used for the research related to the ethically approved protocol.  Also if 
the researchers wish to use your stored specimen for additional research in the field of MS they 
will be required to apply for permission to do so from the Human Research Ethics Committee at 
Stellenbosch University that can be contacted at telephone number 021 938 9657. If you do not 
wish your specimens to be stored after this research study is completed you will have an 
opportunity to request that it be discarded when you sign the consent form without any effect on 
your treatment. If you do not wish your blood specimen to be stored after this research study is 
completed you will have an opportunity to request that it be discarded when you sign the consent 
form. 
 
How will your confidentiality be protected? 
The specimens will be given an ID number and only the researchers and clinicians involved in the 
study will have access to the original questionnaires and assessment forms with identifying 
information. Specimens sent to other laboratories local or abroad will be shipped only with the ID 
number attached to them and your name will not be disclosed to the collaborator. If ever 
information comes to light that could be important for the individual or her descendants, all possible 
attempts will be made to contact these participants and counsel them. The results of the study will 
be included in scientific articles and student theses, without revealing the identity of the study 
participants. 
 
Will you or the researchers benefit financially from this research? 
 
You will not be paid to take part in this study; however the results from this project may bring 
benefits to you, your family or community in the future. 
 
Important information: In the event that this research leads to the development of a 
commercial application or patent, you or your family will not receive any profits or royalties 
although the researchers may benefit in this respect 
 
  
 Declaration by participant 
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By signing below, I …………………………………..…………. agree to take part in the research study 
entitled: The development of a comprehensive gene-based, pathology supported intervention program 
for improved quality of life in patients diagnosed with multiple sclerosis (MS) 
 
I declare that: 
 I have read or had read to me this information and consent form and it is written in a 
language with which I am fluent and comfortable. 
 I have had a chance to ask questions and all my questions have been adequately 
answered. 
 I understand that taking part in this study is voluntary and I have not been pressurised to 
take part. 
 I have received a signed duplicate copy of this consent form for my records. 
 
 
 
Tick the option you choose: 
 
I agree that my blood or tissue sample can be stored indefinitely but I can choose to request at 
any time time that my stored sample be destroyed. My sample will be identified with a special 
study code that will remain linked to my name and contact details. I have the right to receive 
confirmation that my request has been carried out.  My sample may be shipped to another 
laboratory in SA or abroad to be used in other research projects in this or a related field without 
revealing my identity.  
OR 
I agree that my blood or tissue sample can be stored indefinitely after the project is completed 
but that it is anonymised with all possible links to my identity removed, and that the researchers 
may then use it for additional research in this or a related field. Once my sample is anonymised 
by deleting my name from the data base and destroying this consent form, my rights to the 
sample labelled with only a unique ID number, are waivered. My sample may be shipped to 
another laboratory in SA or abroad to be used in other research projects in this or a related field. 
OR 
 Please destroy my blood sample as soon as the current research project has been completed.   
 
 
 
 
Signed at (place)  ...................................................  on (date)  ............................................... 
 
 
 
 
 
 ...................................................................  ................................................................. 
Signature of participant Signature of witness 
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Declaration by investigator 
 
 
I (name) ………………………………………………… declare that: 
 
 I explained the information in this document to …………………..……………... 
 I encouraged him/her to ask questions and took adequate time to answer them. 
 I am satisfied that he/she adequately understands all aspects of the research as discussed 
above. 
 I did/did not use a interpreter.  (If a interpreter is used then the interpreter must sign the 
declaration below. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....………... 
 
 
 
 ...................................................................  ................................................................. 
Signature of investigator Signature of witness 
 
 
 
Declaration By Interpreter 
 
I (name) ………………………………………………… declare that: 
 
 I assisted the investigator (name) …………………………. to explain the information in 
this document to (name of participant) …………………………….. using the language 
medium of Afrikaans/Xhosa. 
 We encouraged him/her to ask questions and took adequate time to answer them. 
 I conveyed a factually correct version of what was related to me. 
 I am satisfied that the participant fully understands the content of this informed consent 
document and has had all his/her question satisfactorily answered. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2005. 
 
 
 
 ...................................................................  ................................................................. 
Signature of interpreter Signature of witness 
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